Fresenius Medical Care AG & Co. KGaA (FMS) 6-K/A 1 Aug 14 2014 Q2 Current report (foreign) (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Jun. 30, 2014
Document and Entity Information [Abstract]	'
Document period end date	30-Jun-14
Amendment flag	'false
Entity registrant name	'FRESENIUS MEDICAL CARE AG & Co. KGaA
Entity current reporting status	'Yes
Entity voluntary filers	'Yes
Entity central index key	'0001333141
Document type	'6-K
Current fiscal year end date	'--12-31
Entity filer category	'Large Accelerated Filer
Entity well known seasoned issuer	'Yes
Entity common stock shares outstanding	302,303,805
Entity public float	$14,782,656,065
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q2

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net revenue:	'	'	'	'
Dialysis Care Revenue	$3,013,544,000	$2,811,244,000	$5,858,968,000	$5,553,179,000
Valuation Allowances and Reserves, Adjustments	-64,715,000	-67,798,000	-127,952,000	-131,547,000
Net Dialysis care revenue	2,948,829,000	2,743,446,000	5,731,016,000	5,421,632,000
Dialysis Products Revenue	885,973,000	869,069,000	1,667,378,000	1,654,804,000
Net revenue	3,834,802,000	3,612,515,000	7,398,394,000	7,076,436,000
Costs of revenue:	'	'	'	'
Dialysis Care Cost of Revenue	2,201,418,000	2,057,342,000	4,319,022,000	4,041,566,000
Dialysis Products Cost of Revenue	421,966,000	396,800,000	785,822,000	766,979,000
Cost of revenues	2,623,384,000	2,454,142,000	5,104,844,000	4,808,545,000
Gross profit	1,211,418,000	1,158,373,000	2,293,550,000	2,267,891,000
Operating expenses:	'	'	'	'
Selling, general and administrative	630,641,000	595,356,000	1,250,374,000	1,187,070,000
Research and development	30,701,000	30,921,000	60,729,000	61,293,000
Income from equity method investees	-5,969,000	-4,416,000	-18,491,000	-9,224,000
Gain on the sale of dialysis clinics	-228,000	-7,727,000	-230,000	-8,800,000
Operating income	556,273,000	544,239,000	1,001,168,000	1,037,552,000
Other (income) expense:	'	'	'	'
Interest income	-12,899,000	-6,653,000	-28,314,000	-17,242,000
Interest expense	111,305,000	109,704,000	222,981,000	224,522,000
Income before income taxes	457,867,000	441,188,000	806,501,000	830,272,000
Income tax expense	177,291,000	143,613,000	278,575,000	272,614,000
Net Income	280,576,000	297,575,000	527,926,000	557,658,000
Less: Net income attributable to noncontrolling interests	46,934,000	35,051,000	88,822,000	69,635,000
Net Income attributable to the Company	233,642,000	262,524,000	439,104,000	488,023,000
Basic income per Ordinary share	$0.77	$0.86	$1.46	$1.59
Earning Per Share Diluted	$0.77	$0.85	$1.45	$1.59

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	$280,576	$297,575	$527,926	$557,658
Other comprehensive income loss derivatives qualifying as hedges before tax	7,071	3,993	14,030	19,890
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,355	6,390	8,709	12,788
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	37,770	-59,178	-9,286	-127,370
Other comprehensive income loss tax	-3,611	-3,233	-7,161	-9,917
Other comprehensive income (loss), net of tax	45,585	-52,028	6,292	-104,609
Total comprehensive income	326,161	245,547	534,218	453,049
Comprehensive income attributable to Noncontrolling interests	47,216	34,715	89,071	67,317
Comprehensive income attributable to the Company	$278,945	$210,832	$445,147	$385,732

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$644,538	$682,777
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	3,176,410	3,037,274
Accounts receivable from related parties	201,784	153,118
Inventories	1,279,427	1,097,104
Prepaid expenses and other current assets	1,248,233	1,037,391
Deferred tax asset, current	254,768	279,052
Total current assets	6,805,160	6,286,716
Property, plant and equipment, net	3,299,880	3,091,954
Intangible assets	728,093	757,876
Goodwill	11,873,989	11,658,187
Deferred tax asset, non-current	117,461	104,167
Equity Method Investments	737,916	664,446
Other assets	582,758	556,560
Total assets	24,145,257	23,119,906
Current liabilities:	'	'
Accounts payable	559,031	542,597
Accounts payable to related parties	164,499	123,929
Accrued expenses and other current liabilities	2,054,683	2,012,533
Short-term borrowings and other financial liabilities	197,804	96,648
Short-term borrowings from related parties	161,984	62,342
Current portion of long-term debt and capital lease obligations	335,416	511,370
Income tax payable, current	178,032	170,360
Deferred tax liability, current	35,472	34,194
Total current liabilities	3,686,921	3,553,973
Total long-term debt less current maturities	8,444,284	7,746,920
Other liabilities	337,147	329,561
Pension liabilities	436,711	435,858
Income tax payable, non-current	185,476	176,933
Deferred tax liability, non-current	732,330	743,390
Total liabilities	13,822,869	12,986,635
Noncontrolling interests subject to put provisions	672,234	648,251
Company shareholders' equity:	'	'
Common stock, no par value, 1.00 Euro nominal value, 392,462,972 shares authorized, 309,111,125 issued and 301,562,174 outstanding	383,586	382,411
Treasury Stock	505,014	505,014
Additional paid-in capital	3,549,022	3,530,337
Retained earnings	6,498,618	6,377,417
Accumulated other comprehensive (loss)	-544,544	-550,587
Total Company shareholders' equity	9,381,668	9,234,564
Minority interest	268,486	250,456
Total equity	9,650,154	9,485,020
Total liabilities and equity	$24,145,257	$23,119,906

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals)	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)
Consolidated Balance Sheets	'	'	'
Trade accounts receivable allowance for doubtful accounts	$403,657	'	$413,165
Preference shares, no par value (in Euros)	'	€ 1	'
Common stock no par value (in Euros)	'	€ 1	'
Common stock authorized	392,462,972	392,462,972	'
Common stock issued	309,111,125	309,111,125	'
Common stock outstanding	301,562,174	301,562,174	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating Activities:	'	'
Net Income	$527,926	$557,658
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	336,126	315,154
Change in deferred taxes, net	692	-529
(Gain) loss on sale of investments	-230	-8,800
(Gain) loss on sale of fixed assets	1,774	2,546
Stock Option Compensation Expense	-1,403	12,777
Dividend income from equity method investees	28,737	14,751
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	-93,529	-62,574
Inventories, net	-180,098	-34,265
Prepaid expenses, other current and non-current assets	-66,742	22,735
Accounts receivable, related parties	-27,465	-56,774
Accounts payable, related parties	41,652	78,094
Accounts payable, accrued expenses and other current and non-current liabilities	-7,651	-9,009
Income tax payable	1,818	12,801
Net cash provided by (used in) operating activities	561,607	840,537
Investing Activities:	'	'
Purchases of property, plant and equipment	-419,259	-333,642
Proceeds from sale of property, plant and equipment	4,291	14,796
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	-434,697	-101,809
Proceeds from divestitures	3,310	17,824
Net cash (used in) provided by investing activities	-846,355	-402,831
Financing Activities:	'	'
Proceeds from short-term borrowings and other financial liabilities	137,213	64,703
Repayments of short-term borrowings and other financial liabilities	-50,583	-62,148
Proceeds from short-term borrowings from related parties	158,407	4,203
Repayments of short-term borrowings from related parties	'	-5,819
Proceeds from long-term debt and capital lease obligations (net of debt issuance costs and other hedging costs of $156,391 in 2012)	786,242	203,080
Repayments of long-term debt and capital lease obligations	-450,277	-169,796
Increase (decrease) of accounts receivable securitization program	72,000	23,000
Proceeds from exercise of stock options	40,753	36,142
Proceeds from conversion of preference shares into ordinary shares	-97,047	'
Distributions to Noncontrolling interests	'	-117,855
Contributions from noncontrolling interests	25,323	27,157
Cash provided by (used in) financing activities	247,370	-524,121
Effect of exchange rate changes on cash and cash equivalents	-861	-15,768
Cash and Cash Equivalents:	'	'
Net (decrease) in cash and cash equivalents	-38,239	-102,183
Cash and cash equivalents at beginning of period	682,777	688,040
Cash and cash equivalents at end of period	$644,538	'

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Preferred Stock, No par value [Member]	Common Stock, No par value [Member]	Treasury Stock Equity	Additional paid in capital [Member]	Retained earnings [Member]	Accumulated other comprehensive income (loss) [Member]	Total FMC-AG and Co. KGaA [Member]	Noncontrolling interests not subject to put provisions [Member]
In Thousands, except Share data, unless otherwise specified
Shareholders equity at Dec. 31, 2012	'	'	$374,915	'	$3,491,581	$5,563,661	($492,113)	$8,942,506	$264,754
Shares issued at Dec. 31, 2012	'	3,973,333	302,739,758	'	'	'	'	'	'
Proceeds from exercise of options and related tax effects	105,554	3	3,031	'	102,520	'	'	105,554	'
Shares from exercise of options and related tax effects	'	2,200	2,280,439	'	'	'	'	'	'
Proceeds from conversion of preference shares	34,784	-4,465	'	'	34,784	'	'	34,784	'
Preference share conversion	'	-3,975,533	3,975,533	'	'	'	'	'	'
Compensation expense related to stock options	-13,593	'	'	'	-13,593	'	'	-13,593	'
Dividends paid	296,134	'	'	'	'	296,134	'	296,134	'
treasury stock value	-505,014	'	'	-505,014	'	'	'	-505,014	'
treasury stock shares	'	'	'	-7,548,951	'	'	'	'	'
Purchase/sale of noncontrolling interests	-15,173	'	'	'	-3,566	'	'	-3,566	-11,607
Minority interest decrease from distributions to noncontrolling interest holders	-32,275	'	'	'	'	'	'	'	-32,275
Changes in fair value of noncontrolling interests	-108,575	'	'	'	-108,575	'	'	-108,575	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	-61,467	'	'	'	'	'	-58,474	-58,474	-2,993
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	1,142,467	'	'	'	'	1,109,890	'	1,109,890	32,577
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	1,081,000	'	'	'	'	'	'	1,051,416	29,584
Shareholders equity at Dec. 31, 2013	9,485,020	'	'	-505,014	'	6,377,417	-550,587	9,234,564	250,456
Shares issued at Dec. 31, 2013	'	'	'	-7,548,951	'	'	'	'	'
Shareholders equity at Mar. 31, 2014	'	'	'	'	'	'	'	'	'
Proceeds from exercise of options and related tax effects	40,725	'	1,175	'	39,550	'	'	40,725	'
Shares from exercise of options and related tax effects	'	'	857,026	'	'	'	'	'	'
Compensation expense related to stock options	-1,403	'	'	'	-1,403	'	'	-1,403	'
Dividends paid	317,903	'	'	'	'	317,903	'	317,903	'
Purchase/sale of noncontrolling interests	3,892	'	'	'	-3,053	'	'	-3,053	6,945
Minority interest decrease from distributions to noncontrolling interest holders	-19,660	'	'	'	'	'	'	'	-19,660
Changes in fair value of noncontrolling interests	-16,409	'	'	'	-16,409	'	'	-16,409	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	6,462	'	'	'	'	'	6,043	6,043	419
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	469,430	'	'	'	'	439,104	'	439,104	30,326
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	475,892	'	'	'	'	'	'	445,147	30,745
Shareholders equity at Jun. 30, 2014	$9,650,154	'	'	($505,014)	$3,549,022	$6,498,618	($544,544)	$9,381,668	$268,486
Shares issued at Jun. 30, 2014	'	'	'	-7,548,951	'	'	'	'	'

The_Company_Basis_of_Presentat

The Company, Basis of Presentation, Healthcare Reform and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
The Company and Basis of Presentation	'
	1. The Company and Basis of Presentation
	The Company
	Fresenius Medical Care AG & Co. KGaA (“FMC-AG & Co. KGaA” or the “Company”), a German partnership limited by shares (Kommanditgesellschaft auf Aktien), is the world's largest kidney dialysis company, operating in both the field of dialysis care and the field of dialysis products for the treatment of end-stage renal disease (“ESRD”). The Company's dialysis care business, in addition to providing dialysis treatments to patients with ESRD, includes pharmacy services, vascular access surgery services, laboratory testing services, physician services, health plan services and urgent care services (together, “Care Coordination”). The Company's dialysis products business includes manufacturing and distributing products for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a broad range of products. In addition, the Company sells dialysis products to other dialysis service providers. In the United States (“U.S.”), the Company also provides inpatient dialysis services as well as other services under contract to hospitals.
	In these unaudited consolidated financial statements, “FMC-AG & Co. KGaA,” or the “Company,” “we,” “us” or “our” refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term “North America Segment” refers to the Company's North America operating segment and the term “International Segment” refers to the combination of the Europe, Middle East, Africa, and Latin America (“EMEALA”) operating segment and the Asia-Pacific operating segment. For further discussion of our operating segments, see Note 14 “Segment and Corporate Information.”
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	The consolidated financial statements at June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 contained in this report are unaudited and should be read in conjunction with the consolidated financial statements contained in the Company's 2013 Annual Report on Form 20-F. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature.
	The accounting policies applied in the accompanying consolidated financial statements are the same as those applied in the consolidated financial statements at and for the year ended December 31, 2013, contained in the Company's 2013 Annual Report on Form 20-F.
	Certain items, in the net aggregate amount of $6,364 and $11,370 for the three- and six-month periods ending June 30, 2013, respectively, relating to research and development, compensation expense, and income from equity method investees have been reclassified in the prior year's comparative consolidated financial statements between the North America Segment, the International Segment and Corporate, as applicable, to conform to the current year's presentation.
	The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results of operations for the year ending December 31, 2014.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Related Party Transactions	'
	2. Related Party Transactions
	The Company's parent, Fresenius SE & Co. KGaA (“Fresenius SE”), a German partnership limited by shares, owns 100% of the share capital of Fresenius Medical Care Management AG, the Company's general partner (“General Partner”). Fresenius SE is also the Company's largest shareholder and owns approximately 31.2% of the Company's outstanding shares at June 30, 2014. The Company has entered into certain arrangements for services, leases and products with Fresenius SE or its subsidiaries and with certain of the Company's equity method investees as described in item a) below. The Company's terms related to the receivables or payables for these services, leases and products are generally consistent with the normal terms of the Company's ordinary course of business transactions with unrelated parties. Financing arrangements as described in item b) below have agreed upon terms which are determined at the time such financing transactions occur and reflect market rates at the time of the transaction. The relationship between the Company and its related parties that assume the role of key management personnel is described in item c) below. Our related party transactions are settled through Fresenius SE's cash management system where appropriate.
	a)       Service Agreements, Lease Agreements and Products
	The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the “Fresenius SE Companies”) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. The Company also provides certain services to the Fresenius SE Companies, including research and development, central purchasing and warehousing. The Company also performs clinical studies and marketing and distribution services for certain of its equity method investees.
	The Company entered into real estate operating lease agreements with the Fresenius SE Companies, which include leases for the corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany. The majority of the leases expire in 2016 and contain renewal options.
	In addition to the above mentioned service and lease agreements, the Company sold products to the Fresenius SE Companies and made purchases from the Fresenius SE Companies. In addition, Fresenius Medical Care Holdings, Inc. (“FMCH”) purchases heparin supplied by Fresenius Kabi USA, Inc. (“Kabi USA”), through an independent group purchasing organization (“GPO”). Kabi USA is wholly-owned by Fresenius Kabi AG, a wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. FMCH acquires heparin from Kabi USA, through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO.
	The Company entered into an agreement with a Fresenius SE company for the manufacturing of plasma collection devices. The Company agreed to produce 3,500 units, with an option to produce a total of 4,550 units, over the length of the five year contract.
	Below is a summary, including the Company's receivables from and payables to the indicated parties resulting from the above described transactions with related parties.
	b)       Financing
	The Company receives short-term financing from and provides short-term financing to Fresenius SE. The Company also utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties. As of June 30, 2014 and December 31, 2013, the Company had accounts receivables from Fresenius SE related to short-term financing in the amount of $152,851 and $112,568, respectively. As of June 30, 2014 and December 31, 2013, the Company had accounts payables to Fresenius SE related to short-term financing in the amount of $136,095 and $102,731, respectively. The interest rates for these cash management arrangements are set on a daily basis and are based on the then-prevailing overnight reference rate for the respective currencies.
	On June 12, 2014, the Company provided a one year unsecured term loan to one of its equity method investees in the amount of $22,500 with an interest rate of 2.5366%. The loan agreement contains automatic one year renewals and requires a six month termination notice.
	At June 30, 2014, the Company borrowed from Fresenius SE €115,600 ($157,886 at June 30, 2014) on an unsecured basis at an interest rate of 1.474%. Subsequent to June 30, 2014, the Company received additional advances from Fresenius SE increasing the amount borrowed to €288,900 ($394,580) and is due on July 31, 2014. For further information on this loan agreement, see Note 5. “Short-Term Borrowings, Other Financial Liabilities and Short-Term Borrowings from Related Parties – Short-Term Borrowings from Related Parties.”
	On August 19, 2009, the Company borrowed €1,500 ($2,049 at June 30, 2014) from the General Partner on an unsecured basis at 1.335%. The loan repayment has been extended periodically and is currently due August 20, 2014 with an interest rate of 1.796%. On November 28, 2013, the Company borrowed an additional €1,500 ($2,049 at June 30, 2014) from the General Partner at 1.875%. This loan is due on November 28, 2014.
	At June 30, 2014 and December 31, 2013, a subsidiary of Fresenius SE held unsecured Senior Notes issued by the Company in the amount of €11,800 and €11,800 ($16,116 and $16,273), respectively. The Senior Notes were issued in 2011 and 2012, mature on 2021 and 2019, respectively, and have a coupon rate of 5.25% with interest payable semiannually.
	On May 23, 2014, the maturity date, the Company repaid a Chinese Yuan Renminbi (“CNY”) loan, with interest, of 360,794 ($57,854) to a subsidiary of Fresenius SE.
	c)       Key Management Personnel
	Due to the legal form of a German partnership limited by shares, the General Partner holds a key management position within the Company. In addition members of the Management Board and the Supervisory Board as key management personnel, as well as their close relatives, are considered related parties.
	The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the General Partner's management board. The aggregate amount reimbursed to the General Partner was $12,491 and $9,136, respectively, for its management services during the six months ended June 30, 2014 and 2013. As of June 30, 2014 and December 31, 2013, the Company had accounts receivables from the General Partner in the amount of $1,064 and $407, respectively. As of June 30, 2014 and December 31, 2013, the Company had accounts payables to the General Partner in the amount of $17,140 and $9,702, respectively.
	4. Other Assets and Notes Receivables
	On August 12, 2013, FMCH made an investment-type transaction by providing a credit facility to a middle-market dialysis provider (the “Payee”) in the amount of up to $200,000 to fund general corporate purposes. The transaction is in the form of subordinated notes with a maturity date of July 4, 2020 (unless prepaid) and a payment-in-kind (“PIK”) feature that will allow interest payments in the form of cash (at 10.75%) or PIK (at 11.75%). The PIK feature, if used, allows for the addition of the accrued interest to the then outstanding principal. The collateral for this loan is 100% of the equity interest in this middle-market dialysis provider. The availability period for drawdowns on this loan is 18 months ending on February 12, 2015 and amounts drawn whether repaid or prepaid cannot be re-borrowed. The Company assesses the recoverability of this investment based on quarterly financial statements and other information obtained, used for an assessment of profitability and business plan objectives, as well as by analyzing general economic and market conditions in which the provider operates. On April 30, 2014, the Payee exercised the PIK feature and converted $10,137 of accrued interest then due to outstanding principal. Consequently, at June 30, 2014, $180,137 is effectively drawn down with $3,679 of interest income accrued. Interest is payable on a semi-annual basis for the length of the loan.

Inventories

Inventories	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Inventories	'
	3. Inventories
	At June 30, 2014 and December 31, 2013, inventories consisted of the following:
				30-Jun-14		31-Dec-13
	Finished goods		$	807,525	$	640,355
	Health care supplies			197,596		195,519
	Raw materials and purchased components			195,780		185,146
	Work in process			78,526		76,084
		Inventories	$	1,279,427	$	1,097,104

ShortTerm_Borrowings_and_Other

Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties	'
	Short-Term Borrowings, Other Financial Liabilities and Short-Term Borrowings from Related Parties
	At June 30, 2014 and December 31, 2013, short-term borrowings, other financial liabilities and short-term borrowings from related parties consisted of the following:
		30-Jun-14		31-Dec-13
	Borrowings under lines of credit	$	197,567	$	95,690
	Other financial liabilities		237		958
	Short-term borrowings and other financial liabilities		197,804		96,648
	Short-term borrowings from related parties (see Note 2.b)		161,984		62,342
	Short-term borrowings, other financial liabilities and short-term borrowings from related parties	$	359,788	$	158,990
		30-Jun-14		31-Dec-13
	Borrowings under lines of credit	$	197,567	$	95,690
	Other financial liabilities		237		958
	Short-term borrowings and other financial liabilities		197,804		96,648
	Short-term borrowings from related parties (see Note 2.b)		161,984		62,342
	Short-term borrowings, other financial liabilities and short-term borrowings from related parties	$	359,788	$	158,990

Longterm_Debt_and_Capital_Leas

Long-term Debt and Capital Lease Obligations	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Long-term Debt and Capital Lease Obligations	'
	6. Long-Term Debt and Capital Lease Obligations
	At June 30, 2014 and December 31, 2013, long-term debt and capital lease obligations consisted of the following:
		30-Jun-14		31-Dec-13
	2012 Credit Agreement	$	3,267,812	$	2,707,145
	Senior Notes		4,809,561		4,824,753
	Euro Notes		38,413		46,545
	European Investment Bank Agreements (1)		-		193,074
	Accounts receivable facility		423,250		351,250
	Capital lease obligations		46,861		24,264
	Other		193,803		111,259
	Long-term debt and capital lease obligations		8,779,700		8,258,290
	Less current maturities		-335,416		-511,370
	Long-term debt and capital lease obligations, less current portion	$	8,444,284	$	7,746,920
	(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014.
		30-Jun-14		31-Dec-13
	2012 Credit Agreement	$	3,267,812	$	2,707,145
	Senior Notes		4,809,561		4,824,753
	Euro Notes		38,413		46,545
	European Investment Bank Agreements (1)		-		193,074
	Accounts receivable facility		423,250		351,250
	Capital lease obligations		46,861		24,264
	Other		193,803		111,259
	Long-term debt and capital lease obligations		8,779,700		8,258,290
	Less current maturities		-335,416		-511,370
	Long-term debt and capital lease obligations, less current portion	$	8,444,284	$	7,746,920
	(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014.
	2012 Credit Agreement
	The following table shows the available and outstanding amounts under the 2012 Credit Agreement at June 30, 2014 and at December 31, 2013:
		Maximum Amount Available June 30, 2014				Balance Outstanding June 30, 2014
	Revolving Credit USD	$	600,000	$	600,000	$	235,447	$	235,447
	Revolving Credit EUR	€	500,000	$	682,900	€	463,000	$	632,365
	Term Loan A	$	2,400,000	$	2,400,000	$	2,400,000	$	2,400,000
				$	3,682,900			$	3,267,812
		Maximum Amount Available December 31, 2013				Balance Outstanding December 31, 2013
	Revolving Credit USD	$	600,000	$	600,000	$	138,190	$	138,190
	Revolving Credit EUR	€	500,000	$	689,550	€	50,000	$	68,955
	Term Loan A	$	2,500,000	$	2,500,000	$	2,500,000	$	2,500,000
				$	3,789,550			$	2,707,145
	At June 30, 2014 and December 31, 2013, the Company had letters of credit outstanding in the amount of $7,143 and $9,444, respectively, under the revolving credit facility, which are not included above as part of the balance outstanding, but reduce the available borrowings under the revolving credit facility.
	Accounts Receivable Facility
	The following table shows the available and outstanding amounts under the account receivable facility at June 30, 2014 and at December 31, 2013:
			Maximum Amount Available(1)			Balance Outstanding
		30-Jun-14		31-Dec-13		30-Jun-14		31-Dec-13
	Accounts Receivable Facility	$	800,000	$	800,000	$	423,250	$	351,250
	(1) Subject to availability of sufficient accounts receivable meeting funding criteria.
	The Company also had letters of credit outstanding under the accounts receivable facility in the amount of $66,622 as of June 30, 2014 and $65,622 at December 31, 2013. These letters of credit are not included above as part of the balance outstanding at June 30, 2014 and December 31, 2013; however, they reduce available borrowings under the accounts receivable facility.
	11. Commitments and Contingencies

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Earnings Per Share	'
	7. Earnings Per Ordinary Share
	The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per ordinary share computations for the three and six months ended June 30, 2014 and 2013:
		For the three months ended June 30,				For the six months ended June 30,
		2014		2013		2014		2013
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA	$	233,642	$	262,524	$	439,104	$	488,023
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding		301,781,895		302,409,369		301,637,274		302,590,288
	Preference shares outstanding(1)		-		3,842,900		-		3,907,756
	Total weighted average shares outstanding		301,781,895		306,252,269		301,637,274		306,498,044
	Potentially dilutive Ordinary shares		615,485		1,362,863		673,158		1,247,741
	Total weighted average Ordinary shares outstanding assuming dilution		302,397,380		303,772,232		302,310,432		303,838,029
	Basic earnings per share	$	0.77	$	0.86	$	1.46	$	1.59
	Fully diluted earnings per share		0.77		0.85		1.45		1.59
	(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding.

Employee_Benefit_Plans

Employee Benefit Plans	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Employee Benefit Plans	'
	8. Employee Benefit Plans
	The Company currently has two principal pension plans, one for German employees, the other covering employees in the United States, the latter of which was curtailed in 2002. Plan benefits are generally based on years of service and final salary. As there is no legal requirement in Germany to fund defined benefit plans, the Company's pension obligations in Germany are unfunded. Each year FMCH contributes to the plan covering United States employees at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended.
	The following table provides the calculations of net periodic benefit cost for the three and six months ended June 30, 2014 and 2013, respectively.
		For the three months ended June 30,				For the six months ended June 30,
		2014		2013		2014		2013
	Components of net periodic benefit cost:
	Service cost	$	4,743	$	3,879	$	9,482	$	7,792
	Interest cost		7,408		6,758		14,812		13,542
	Expected return on plan assets		-3,925		-3,400		-7,850		-6,800
	Amortization of unrealized losses		4,355		6,390		8,709		12,788
	Net periodic benefit costs	$	12,581	$	13,627	$	25,153	$	27,322

Noncontrolling_Interests_Subje

Noncontrolling Interests Subject to Put Provisions	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	9. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At June 30, 2014 and December 31, 2013, the Company's potential obligations under these put options were $672,234 and $648,251, respectively, of which, at June 30, 2014, put options with an aggregate purchase obligation of $272,417 were exercisable. No put options were exercised during the first six months of 2014.
	The following is a roll forward of noncontrolling interests subject to put provisions for the six months ended June 30, 2014 and the year ended December 31, 2013:
		30-Jun-14		31-Dec-13
	Beginning balance as of January 1,	$	648,251	$	523,260
	Contributions to noncontrolling interests		-60,761		-122,179
	Purchase/ sale of noncontrolling interests		-945		6,723
	Contributions from noncontrolling interests		10,954		17,767
	Changes in fair value of noncontrolling interests		16,409		108,575
	Net income		58,496		113,156
	Other comprehensive income (loss)		-170		949
	Ending balance as of June 30, 2014 and December 31, 2013	$	672,234	$	648,251

Patient_Service_Revenue

Patient Service Revenue	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Patient Service Revenue Text Block 1 [Text Block]	'
	10. Sources of Revenue
	Below is a table showing the sources of our U.S. patient service revenue (net of contractual allowance and discounts but before patient service bad debt provision), included in the Company's dialysis care revenue, for the six months ended June 30, 2014 and 2013. Outside of the U.S., the Company does not recognize patient service revenue at the time the services are rendered without assessing the patient's ability to pay. Accordingly, the additional disclosure requirements introduced with ASU 2011-07 only apply to the U.S. patient service revenue.
		For the six months ended June 30,
			2014		2013
	Medicare ESRD program	$	2,208,586	$	2,131,095
	Private/alternative payors		2,013,357		1,865,556
	Medicaid and other government sources		202,892		186,059
	Hospitals		220,201		209,517
	Total patient service revenue	$	4,645,036	$	4,392,227

Financial_Instruments

Financial Instruments	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Financial Instruments	'
	12. Financial Instruments
	Non-derivative Financial Instruments
	The following table presents the carrying amounts and fair values of the Company's non-derivative financial instruments at June 30, 2014, and December 31, 2013.
						June 30,						December 31,
						2014						2013
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	644,538			644,538		$	682,777			682,777
		Accounts Receivable(1)	2			3,378,194			3,378,194			3,190,392			3,190,392
		Notes Receivable	3			177,018			192,672			165,807			175,768
	Liabilities
		Accounts payable(1)	2			723,530			723,530			666,526			666,526
		Short-term borrowings(1)	2			359,788			359,788			158,990			158,990
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			663,914			663,914			679,847			679,847
		2012 Credit Agreement	2			3,267,812			3,264,812			2,707,145			2,710,270
		Senior Notes	2			4,809,561			5,396,239			4,824,753			5,348,679
		Euro Notes	2			38,413			39,041			46,545			47,423
	Noncontrolling interests subject to put provisions		3			672,234			672,234			648,251			648,251
	(1) Also includes amounts receivable from or payable to related parties.
	The carrying amounts in the table are included in the consolidated balance sheet under the indicated captions or in the case of long-term debt, in the captions shown in Note 6.
	The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows:
	Cash and cash equivalents are stated at nominal value which equals the fair value.
	Short-term financial instruments such as accounts receivable, accounts payable and short-term borrowings are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments.
	The valuation of notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company's industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value.
	The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.
	The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 9 for a discussion of the Company's methodology for estimating the fair value of these noncontrolling interests subject to put obligations.
	Currently, there is no indication that a decrease in the value of the Company's financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial.
	Derivative Financial Instruments
	The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.
	In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes.
	The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other.
	To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.
	The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in its Consolidated Balance Sheets.
	At June 30, 2014 and December 31, 2013, the Company had $7,122 and $18,334 of derivative financial assets subject to netting arrangements and $19,456 and $16,371 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $2,060 and $12,169 as well as net liabilities of $14,394 and $10,207 at June 30, 2014 and December 31, 2013, respectively.
	Foreign Exchange Risk Management
	The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements.
	The Company's exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At June 30, 2014 and December 31, 2013, the Company had no foreign exchange options.
	Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in Accumulated Other Comprehensive Income (“AOCI”). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $144,173 and $238,983 at June 30, 2014 and December 31, 2013, respectively.
	The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currency that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these two cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,562,841 and $1,512,559 at June 30, 2014 and December 31, 2013, respectively.
	Interest Rate Risk Management
	The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2016 and have an interest rate of 1.73%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense.
	At June 30, 2014 and December 31, 2013, the notional amount of the euro-denominated interest rate swaps in place was €100,000 and €100,000 ($136,580 and $137,910 at June 30, 2014 and December 31, 2013, respectively).
	In addition, the Company also enters into interest rate hedges (“pre-hedges”) in anticipation of future debt issuance to effectively convert the variable interest rate related to the future debt to a fixed interest rate. These pre-hedges are settled at the issuance date of the corresponding debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the pre-hedges. At June 30, 2014 and December 31, 2013, the Company had $107,229 and $118,844, respectively, related to such settlements of pre-hedges deferred in AOCI, net of tax.
	Derivative Financial Instruments Valuation
	The following table shows the carrying amounts of the Company's derivatives at June 30, 2014 and December 31, 2013.
				30-Jun-14						31-Dec-13
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		2,235			-3,936			4,985			-2,719
		Non-current
			Foreign exchange contracts		-			-			759			-374
			Interest rate contracts		-			-4,720			-			-4,392
	Total			$	2,235		$	-8,656		$	5,744		$	-7,485
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		4,579			-12,714			11,679			-22,982
		Non-current
			Foreign exchange contracts		308			-744			1,060			-820
	Total			$	4,887		$	-13,458		$	12,739		$	-23,802
	(1) At June 30, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively.
The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows:
The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency.
The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments.
			Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
Derivatives in Cash Flow Hedging Relationships
			(Effective Portion)										(Effective Portion)
			for the six months ended June 30,										for the six months ended June 30,
			2014			2013		(Effective Portion)				2014			2013
Interest rate contracts		$	1,279		$	3,585		Interest income/expense			$	14,680		$	13,094
Foreign exchange contracts			-4,224			1,962		Costs of Revenue				2,295			514
Foreign exchange contracts								Interest income/expense				-			735
		$	-2,945		$	5,547					$	16,975		$	14,343
Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives
			Location of (Gain) or Loss Recognized in Income on Derivative
						for the six months ended June 30,
						2014			2013
Foreign exchange contracts			Selling, general and administrative expense		$	5,410		$	-42,134
Foreign exchange contracts			Interest income/expense			4,219			3,397
					$	9,629		$	-38,737
For foreign exchange derivatives, the Company expects to recognize $867 of losses deferred in AOCI at June 30, 2014, in earnings during the next twelve months.
The Company expects to incur additional interest expense of $23,589 over the next twelve months which is currently deferred in AOCI. At June 30, 2014, this amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the remaining interest rate swap maturing in 2016.
At June 30, 2014, the Company had foreign exchange derivatives with maturities of up to 18 months and interest rate swaps with maturities of up to 28 months.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Commitments and Contingencies	'
	Legal and Regulatory Matters
	The Company is routinely involved in numerous claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.
	Commercial Litigation
	On April 4, 2003, FMCH filed a suit in the U. S. District Court for the Northern District of California, styled Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter's patents. In general, the asserted patents concern the use of touch screen interfaces for hemodialysis machines. Baxter filed counterclaims against FMCH seeking more than $140,000 in monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter's patents. On July 17, 2006, the court entered judgment on a jury verdict in favor of FMCH finding all asserted claims of Baxter patents invalid as obvious and/or anticipated in light of prior art.
	On February 13, 2007, the court granted Baxter's motion to set aside the jury's verdict in favor of FMCH and reinstated the patents and entered judgment of infringement. Following a trial on damages, the court entered judgment on November 6, 2007 in favor of Baxter on a jury award of $14,300. On April 4, 2008, the court denied Baxter's motion for a new trial, established a royalty payable to Baxter of 10% of the sales price for continuing sales of FMCH's 2008K hemodialysis machines and 7% of the sales price of related disposables, parts and service beginning November 7, 2007, and enjoined sales of the touchscreen-equipped 2008K machine effective January 1, 2009. The Company appealed the court's rulings to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). On September 10, 2009, the Federal Circuit reversed the district court's decision and determined that the asserted claims in two of the three patents at issue are invalid. As to the third patent, the Federal Circuit affirmed the district court's decision; however, the Court also vacated the injunction and award of damages. These issues were remanded to the District Court for reconsideration in light of the invalidity ruling on most of the claims. Upon remand, the district court reduced the post-verdict damages award to $10,000. Separately, the U.S. Patent and Trademark Office (“USPTO”) and the Board of Patent Appeals and Interferences ruled that the remaining Baxter patent is invalid. On May 17, 2012 the Federal Circuit affirmed the USPTO's ruling and invalidated the final remaining Baxter patent. Baxter appealed to the Federal Circuit claiming that approximately $20,000 of damages awarded to it by the District Court before the Federal Circuit affirmed the USPTO ruling constituted a final judgment that may be collected. On July 2, 2013, the Federal Circuit denied Baxter's appeal and ordered the District Court to dismiss the case. The court-approved escrow account has been terminated and the escrow funds have been returned to FMCH. On March 5, 2014, Baxter petitioned the United States Supreme Court to review the decisions of the Federal Circuit. On May 19, 2014, the U.S. Supreme Court denied Baxter's petition and let stand the Federal Circuit's order dismissing the case.
	On August 27, 2012, Baxter filed suit in the U.S. District Court for the Northern District of Illinois, styled Baxter International Inc., et al., v. Fresenius Medical Care Holdings, Inc., Case No. 12-cv-06890, alleging that the Company's LibertyTM cycler infringes certain U.S. patents that were issued to Baxter between October 2010 and June 2012. The Company believes it has valid defenses to these claims, and will defend this litigation vigorously.
	On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that the numerous lawsuits filed and anticipated to be filed in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's acid concentrate products NaturaLyte® and Granuflo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts, styled In Re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. The Massachusetts state courts subsequently established a similar consolidated litigation for such cases filed in Massachusetts county courts, styled In Re: Consolidated Fresenius Cases, Case No. MICV 2013-03400-O (Massachusetts Superior Court, Middlesex County). These lawsuits allege generally that inadequate labeling and warnings for these products caused harm to patients. In addition, similar cases have been filed in state courts outside Massachusetts, in some of which the judicial authorities have established consolidated proceedings for their disposition. FMCH believes that these lawsuits are without merit, and will defend them vigorously.
	Other Litigation and Potential Exposures
	On February 15, 2011, a qui tam relator's complaint under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. The United States has not intervened in the case United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleges that the Company seeks and receives reimbursement from government payors for serum ferritin and hepatitis B laboratory tests that are medically unnecessary or not properly ordered by a physician. On March 6, 2011, the United States Attorney for the District of Massachusetts issued a subpoena seeking the production of documents related to the same laboratory tests that are the subject of the relator's complaint. FMCH has cooperated fully in responding to the subpoena, and will vigorously contest the relator's complaint.
	Subpoenas or search warrants have been issued by federal and state law enforcement authorities under the supervision of the United States Attorneys for the Districts of Connecticut, Southern Florida, Eastern Virginia and Rhode Island to American Access Care LLC (AAC), which the Company acquired in October 2011, and to the Company's Fresenius Vascular Access subsidiary which now operates former AAC centers as well as its own original facilities. Subpoenas have also been issued to certain of the Company's outpatient hemodialysis facilities for records relating to vascular access treatment and monitoring. The Company is cooperating fully in these investigations. Communications with certain of the investigating United States Attorney Offices indicate that the inquiry encompasses invoicing and coding for procedures commonly performed in vascular access centers and the documentary support for the medical necessity of such procedures. The AAC acquisition agreement contains customary indemnification obligations with respect to breaches of representations, warranties or covenants and certain other specified matters. As of October 18, 2013, a group of the prior owners of AAC exercised their right pursuant to the terms of the acquisition agreement to assume responsibility for responding to certain of the subpoenas. Pursuant to the AAC acquisition agreement the prior owners are obligated to indemnify the Company for certain liabilities that might arise from those subpoenas.
	The Company has received communications alleging conduct in countries outside the U.S. and Germany that may violate the U.S. Foreign Corrupt Practices Act (“FCPA”) or other anti-bribery laws. The Audit and Corporate Governance Committee of the Company's Supervisory Board is conducting an investigation with the assistance of independent counsel. The Company voluntarily advised the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”). The Company's investigation and dialogue with the SEC and DOJ are ongoing. The Company has received a subpoena from the SEC requesting additional documents and a request from the DOJ for copies of the documents provided to the SEC. The Company is cooperating with the requests.
	Conduct has been identified that may result in monetary penalties or other sanctions under the FCPA or other anti-bribery laws. In addition, the Company's ability to conduct business in certain jurisdictions could be negatively impacted. The Company has previously recorded a non-material accrual for an identified matter. Given the current status of the investigations and remediation activities, the Company cannot reasonably estimate the range of possible loss that may result from identified matters or from the final outcome of the investigations or remediation activities.
	The Company's independent counsel, in conjunction with the Company's Compliance Department, have reviewed the Company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, and appropriate enhancements are being implemented. The Company is fully committed to FCPA compliance.
	In December 2012 and January 2013, FMCH received subpoenas from the United States Attorneys for the District of Massachusetts and the Western District of Louisiana requesting production of a broad range of documents. Communications with the investigating United States Attorney Offices indicate that the inquiry relates to products manufactured by FMCH, which encompasses the Granuflo® and Naturalyte® acid concentrate products that are also the subject of personal injury litigation described above, as well as electron-beam sterilization of dialyzers, the Liberty peritoneal dialysis cycler, and 2008 series hemodialysis machines as related to the use of Granuflo® and Naturalyte®. FMCH is cooperating fully in the government's investigation.
	On June 13, 2014, the Ministry of Commerce of the People's Republic of China, (MOFCOM) launched an anti-dumping investigation into producers of hemodialysis equipment in the European Union and Japan, which includes certain of the Company's subsidiaries. The Company intends to cooperate in this investigation.
	The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's deductions for civil settlement payments taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the refund amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston).
	From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.
	The Company, like other healthcare providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the FDA and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls, injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. FMCH is currently engaged in remediation efforts with respect to three pending FDA warning letters. See “Regulatory and Legal Matters – Product Regulation” section of the 2013 Annual Report on Form 20-F for additional information. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “qui tam” or “whistle blower” actions. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal.
	The Company operates many facilities throughout the United States and other parts of the world. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act and the Foreign Corrupt Practices Act, among other laws and comparable laws of other countries.
	Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.
	The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business

Business_Segment_Information

Business Segment Information	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Business Segment Information	'
	14. Segment and Corporate Information
	The Company has identified three operating segments, North America Segment, EMEALA and Asia-Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis care services and the distribution of products and equipment for the treatment of ESRD. For reporting purposes, the Company has aggregated the EMEALA and Asia-Pacific operating segments as the “International Segment.” The segments are aggregated due to their similar economic characteristics. These characteristics include same services provided and same products sold, the same type of patient population, similar methods of distribution of products and services and similar economic environments. The General Partner's management board member responsible for the profitability and cash flow of each segment's various businesses supervises the management of each operating segment. The accounting policies of the segments are the same as those the Company applies in preparing the consolidated financial statements under U.S. GAAP.
	Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate U.S. GAAP measures are revenue, operating income and operating income margin. The Company does not include income taxes as it believes this is outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs, which relate primarily to certain headquarters overhead charges, including accounting and finance, etc. (“Corporate”), because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement are centrally managed at Corporate by Global Manufacturing Operations. The Company's global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as Corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but accounted for as Corporate.
	Information pertaining to the Company's segment and Corporate activities for the three- and six-month periods ended June 30, 2014 and 2013 is set forth below.
					North America Segment		International Segment		Segment Totals		Corporate		Total
	Three months ended June 30, 2014
		Net revenue external customers		$	2,520,988	$	1,296,620	$	3,817,608	$	17,194	$	3,834,802
		Inter - segment revenue			2,269		-		2,269		-2,269		-
		Revenue			2,523,257		1,296,620		3,819,877		14,925		3,834,802
		Depreciation and amortization			-87,173		-46,312		-133,485		-35,474		-168,959
		Operating income			400,714		243,009		643,723		-87,450		556,273
		Income (loss) from equity method investees			3,818		2,151		5,969		-		5,969
		Capital expenditures, acquisitions and investments			283,350		180,734		464,084		53,084		517,168
	Three months ended June 30, 2013
		Net revenue external customers		$	2,375,247	$	1,228,322	$	3,603,569	$	8,946	$	3,612,515
		Inter - segment revenue			1,771		-		1,771		-1,771		-
		Revenue			2,377,018		1,228,322		3,605,340		7,175		3,612,515
		Depreciation and amortization(1)			-81,466		-46,432		-127,898		-30,903		-158,801
		Operating income (2)			390,655		218,479		609,134		-64,895		544,239
		Income (loss) from equity method investees(3)			2,871		1,545		4,416		-		4,416
		Capital expenditures, acquisitions and investments			107,948		66,175		174,123		41,757		215,880
	Six months ended June 30, 2014
		Net revenue external customers		$	4,913,894	$	2,457,517	$	7,371,411	$	26,983	$	7,398,394
		Inter - segment revenue			3,549		-		3,549		-3,549		-
		Revenue			4,917,443		2,457,517		7,374,960		23,434		7,398,394
		Depreciation and amortization			-174,822		-91,333		-266,155		-69,971		-336,126
		Operating Income			736,276		423,455		1,159,731		-158,563		1,001,168
		Income (loss) from equity method investees			14,368		4,123		18,491		-		18,491
		Segment assets			15,060,591		6,761,277		21,821,868		2,323,389		24,145,257
			thereof investments in equity method investees		306,313		431,603		737,916		-		737,916
		Capital expenditures, acquisitions and investments(4)			488,249		245,371		733,620		120,336		853,956
	Six months ended June 30, 2013
		Net revenue external customers		$	4,662,497	$	2,396,974	$	7,059,471	$	16,965	$	7,076,436
		Inter - segment revenue			2,846		-		2,846		-2,846		-
		Revenue			4,665,343		2,396,974		7,062,317		14,119		7,076,436
		Depreciation and amortization(1)			-161,873		-92,332		-254,205		-60,949		-315,154
		Operating Income(2)			756,703		410,096		1,166,799		-129,247		1,037,552
		Income (loss) from equity method investees(3)			5,989		3,235		9,224		-		9,224
		Segment assets			14,094,573		5,971,984		20,066,557		2,261,790		22,328,347
			thereof investments in equity method investees		247,277		370,153		617,430		-		617,430
		Capital expenditures, acquisitions and investments(4)			220,280		148,877		369,157		66,294		435,451
		(1) Depreciation in the amount of $988 and $1,884 for the three and six months ended June 30, 2013, respectively, relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(2) Certain items, in the net aggregate amount of $6,364 and $11,370 for the three and six months ended June 30, 2013, respectively, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable.
		(3) Income (loss) from equity method investees in the amount of $717 and $321 for the three and six months ended June 30, 2013, respectively, has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(4) International acquisitions exclude $167,905 and $11,684 of non-cash acquisitions for 2014 and 2013, respectively.

Other_Comprehensive_Income

Other Comprehensive Income	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Other Comprehensive Income	'
	13. Other Comprehensive Income (Loss), net of tax
	Changes in AOCI, net of tax, by component for the six months ended June 30, 2014 and 2013 are as follows:
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (Loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		4,902			-			-125,052		-120,150		-2,318		-122,468
		Amounts reclassified from AOCI		9,974			7,885			-		17,859		-		17,859
	Other comprehensive income (loss) after reclassifications			14,876			7,885			-125,052		-102,291		-2,318		-104,609
	Balance at June 30, 2013		$	-123,465		$	-171,538		$	-299,401	$	-594,404	$	551	$	-593,853
	Balance at December 31, 2013		$	-121,856		$	-141,987		$	-286,744	$	-550,587	$	825	$	-549,762
		Other comprehensive income (loss) before reclassifications		-2,057			-			-9,535		-11,592		249		-11,343
		Amounts reclassified from AOCI		12,146			5,489			-		17,635		-		17,635
	Other comprehensive income (loss) after reclassifications			10,089			5,489			-9,535		6,043		249		6,292
	Balance at June 30, 2014		$	-111,767		$	-136,498		$	-296,279	$	-544,544	$	1,074	$	-543,470
	Reclassifications out of AOCI for the six months ended June 30, 2014 and 2013 are as follows:
	Details about AOCI Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the six months ended June 30,
				2014			2013
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	14,680		$	13,094		Interest income/expense
		Foreign exchange contracts			2,295			514		Costs of Revenue
		Foreign exchange contracts			-			735		Interest income/expense
					16,975			14,343		Total before tax
					-4,829			-4,369		Tax expense or benefit
				$	12,146		$	9,974		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) loss			8,709			12,788		-1
					8,709			12,788		Total before tax
					-3,220			-4,903		Tax expense or benefit
				$	5,489		$	7,885		Net of tax
	Total reclassifications for the period			$	17,635		$	17,859		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 8 for additional details).

Supplementary_Cash_Flow_Inform

Supplementary Cash Flow Information	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Cash Flow Supplemental Disclosures [Text Block]	'
	15. Supplementary Cash Flow Information
	The following additional information is provided with respect to the consolidated statements of cash flows:
			For the six months ended June 30,
			2014		2013
	Supplementary cash flow information:
		Cash paid for interest	$	189,038	$	191,259
		Cash paid for income taxes (1)	$	304,785	$	225,740
		Cash inflow for income taxes from stock option exercises	$	3,153	$	3,933
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-523,912	$	-130,864
		Liabilities assumed		241,132		17,173
		Noncontrolling interest subject to put provisions		3,110		15,320
		Noncontrolling interest		6,191		5,570
		Pending payments for purchase considerations		9,156		11,683
		Cash paid		-264,323		-81,118
		Less cash acquired		84,694		5,139
		Net cash paid for acquisitions		-179,629		-75,979
		Cash paid for investments		-249,156		-22,894
		Cash paid for intangible assets		-5,912		-2,936
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-434,697	$	-101,809
		(1) Net of tax refund.

Supplemental_Condensed_Combini

Supplemental Condensed Combining Information	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Supplemental Condensed Combining Information	'
	17. Supplemental Condensed Combining Information
	FMC Finance III, a former wholly-owned subsidiary of the Company, issued 6⅞% Senior Notes due 2017 in July 2007. On June 20, 2011, Fresenius Medical Care US Finance, Inc. (“US Finance”) acquired substantially all of the assets of FMC Finance III and assumed its obligations, including the 6⅞% Senior Notes and the related indenture. The 6⅞% Senior Notes are fully and unconditionally guaranteed, jointly and severally on a senior basis, by the Company and by FMCH and Fresenius Medical Care Deutschland GmbH (“D-GmbH”), together the (“Guarantor Subsidiaries”). The 6⅞% Senior Notes and related guarantees were issued in an exchange offer registered under the Securities Act of 1933. The financial statements in this report present the financial condition, results of operations and cash flows of the Company, on a consolidated basis at June 30, 2014 and December 31, 2013 and for the six-month periods ended June 30, 2014 and 2013. The following combining financial information for the Company is at June 30, 2014 and December 31, 2013 and for the six-month periods ended June 30, 2014 and 2013, segregated between FMC US Finance as issuer, the Company, D-GmbH and FMCH as guarantors, and the Company's other businesses (the “Non-Guarantor Subsidiaries”). For purposes of the condensed combining information, the Company and the Guarantor Subsidiaries carry their investments under the equity method. Other (income) expense includes income (loss) related to investments in consolidated subsidiaries recorded under the equity method for purposes of the condensed combining information. In addition, other (income) expense includes income and losses from profit and loss transfer agreements as well as dividends received.
			For the six months ended June 30, 2014
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,092,279		$	-		$	8,085,343		$	-1,779,228		$	7,398,394
	Cost of revenue			-			-			691,930			-			6,160,749			-1,747,835			5,104,844
		Gross profit		-			-			400,349			-			1,924,594			-31,393			2,293,550
	Operating expenses (income):
		Selling, general and administrative(1)		-			83,548			84,853			-24,234			1,074,154			13,332			1,231,653
		Research and development		-			-			38,761			-			21,968			-			60,729
	Operating (loss) income			-			-83,548			276,735			24,234			828,472			-44,725			1,001,168
	Other (income) expense:
		Interest, net		-3,461			122,940			-2,928			90,665			-12,549			-			194,667
		Other, net		-			-671,761			202,485			-374,253			-			843,529			-
	Income (loss) before income taxes			3,461			465,273			77,178			307,822			841,021			-888,254			806,501
		Income tax expense (benefit)		1,273			26,169			74,033			-26,207			345,468			-142,161			278,575
	Net Income (loss)			2,188			439,104			3,145			334,029			495,553			-746,093			527,926
	Net Income attributable to noncontrolling interests			-			-			-			-			-			88,822			88,822
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-834,915		$	439,104
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the six months ended June 30, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,006,662		$	-		$	7,664,410		$	-1,594,636		$	7,076,436
	Cost of revenue			-			-			663,055			-			5,719,837			-1,574,347			4,808,545
		Gross profit		-			-			343,607			-			1,944,573			-20,289			2,267,891
	Operating expenses (income):
		Selling, general and administrative (1)		-			40,547			106,983			37,920			964,028			19,568			1,169,046
		Research and development		-			-			36,549			-			24,912			-168			61,293
	Operating (loss) income			-			-40,547			200,075			-37,920			955,633			-39,689			1,037,552
	Other (income) expense:
		Interest, net		-3,417			95,049			3,804			87,078			24,349			417			207,280
		Other, net		-			-615,001			164,333			-432,819			-			883,487			-
	Income (loss) before income taxes			3,417			479,405			31,938			307,821			931,284			-923,593			830,272
		Income tax expense (benefit)		1,240			-8,618			37,248			-49,312			322,357			-30,301			272,614
	Net Income (loss)			2,177			488,023			-5,310			357,133			608,927			-893,292			557,658
	Net Income attributable to noncontrolling interests			-			-			-			-			-			69,635			69,635
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	2,177		$	488,023		$	-5,310		$	357,133		$	608,927		$	-962,927		$	488,023
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
				For the six months ended June 30, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-746,093		$	527,926
		Gain (loss) related to cash flow hedges			-			16,076			-			-			-2,046			-			14,030
		Actuarial gain (loss) on defined benefit pension plans			-			99			1,894			6,524			192			-			8,709
		Gain (loss) related to foreign currency translation			-			36,765			-7,260			-			-38,509			-282			-9,286
		Income tax (expense) benefit related to components of other comprehensive income			-			-4,646			-553			-2,574			612			-			-7,161
	Other comprehensive income (loss), net of tax				-			48,294			-5,919			3,950			-39,751			-282			6,292
	Total comprehensive income			$	2,188		$	487,398		$	-2,774		$	337,979		$	455,802		$	-746,375		$	534,218
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			89,071			89,071
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	2,188		$	487,398		$	-2,774		$	337,979		$	455,802		$	-835,446		$	445,147
				For the six months ended June 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	2,177		$	488,023		$	-5,310		$	357,133		$	608,927		$	-893,292		$	557,658
		Gain (loss) related to cash flow hedges			-			14,431			-			-			5,459			-			19,890
		Actuarial gain (loss) on defined benefit pension plans			-			65			1,267			11,335			121			-			12,788
		Gain (loss) related to foreign currency translation			-			27,707			-6,535			-			-154,575			6,033			-127,370
		Income tax (expense) benefit related to components of other comprehensive income			-			-4,162			-369			-4,472			-914			-			-9,917
	Other comprehensive income (loss), net of tax				-			38,041			-5,637			6,863			-149,909			6,033			-104,609
	Total comprehensive income			$	2,177		$	526,064		$	-10,947		$	363,996		$	459,018		$	-887,259		$	453,049
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			67,317			67,317
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	2,177		$	526,064		$	-10,947		$	363,996		$	459,018		$	-954,576		$	385,732
			At June 30, 2014
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	0		$	2,611		$	8,033		$	-		$	632,579		$	1,315		$	644,538
	Trade accounts receivable, less allowance for doubtful accounts			-			-			154,243			-			3,020,417			1,750			3,176,410
	Accounts receivable from related parties			1,267,108			1,351,662			1,040,410			1,654,545			4,297,558			-9,409,499			201,784
	Inventories			-			-			314,662			-			1,129,355			-164,590			1,279,427
	Prepaid expenses and other current assets			-			49,754			56,457			67			1,090,101			51,854			1,248,233
	Deferred taxes			-			-			-			-			299,458			-44,690			254,768
		Total current assets		1,267,108			1,404,027			1,573,805			1,654,612			10,469,468			-9,563,860			6,805,160
Property, plant and equipment, net				-			651			257,430			-			3,168,807			-127,008			3,299,880
Intangible assets				-			270			68,318			-			659,594			-89			728,093
Goodwill				-			-			62,223			-			11,811,766			-			11,873,989
Deferred taxes				-			85,060			14,829			-			128,624			-111,052			117,461
Other assets and notes receivables(1)				-			14,258,249			57,611			12,894,961			5,068,002			-30,958,149			1,320,674
	Total assets		$	1,267,108		$	15,748,257		$	2,034,216		$	14,549,573		$	31,306,261		$	-40,760,158		$	24,145,257
Current liabilities:
	Accounts payable		$	-		$	651		$	32,873		$	-		$	525,507		$	-		$	559,031
	Accounts payable to related parties			-			2,032,970			785,342			1,602,668			5,394,855			-9,651,336			164,499
	Accrued expenses and other current liabilities			29,771			54,308			154,350			9,346			1,802,668			4,240			2,054,683
	Short-term borrowings			-			68,290			-			-			129,514			-			197,804
	Short-term borrowings from related parties			-			-			-			-			161,984			-			161,984
	Current portion of long-term debt and capital lease obligations			-			68,749			-			200,000			66,667			-			335,416
	Income tax payable			-			117,578			-			-			58,684			1,770			178,032
	Deferred taxes			-			1,259			10,598			-			66,651			-43,036			35,472
		Total current liabilities		29,771			2,343,805			983,163			1,812,014			8,206,530			-9,688,362			3,686,921
Long term debt and capital lease obligations, less current portion				1,165,000			646,406			-			2,435,447			7,390,784			-3,193,353			8,444,284
Long term borrowings from related parties				-			3,328,094			-			2,076,579			5,985			-5,410,658			-
Other liabilities				-			5,340			5,644			-			302,918			23,245			337,147
Pension liabilities				-			12,395			261,351			-			162,965			-			436,711
Income tax payable				580			30,549			-			-			24,791			129,556			185,476
Deferred taxes				-			-			-			-			757,995			-25,665			732,330
		Total liabilities		1,195,351			6,366,589			1,250,158			6,324,040			16,851,968			-18,165,237			13,822,869
Noncontrolling interests subject to put provisions				-			-			0			-			672,234			-			672,234
Redeemable Preferred Stock				-			-			-			235,141			-235,141			-			-
Total FMC-AG & Co. KGaA shareholders' equity				71,757			9,381,668			784,058			7,990,392			13,748,714			-22,594,921			9,381,668
Noncontrolling interests not subject to put provisions				-			-			-			-			268,486			-			268,486
Total equity				71,757			9,381,668			784,058			7,990,392			14,017,200			-22,594,921			9,650,154
	Total liabilities and equity		$	1,267,108		$	15,748,257		$	2,034,216		$	14,549,573		$	31,306,261		$	-40,760,158		$	24,145,257
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
			At December 31, 2013
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	0		$	13		$	4,490		$	-		$	672,206		$	6,068		$	682,777
	Trade accounts receivable, less allowance for doubtful accounts			-			-			152,480			-			2,882,736			2,058			3,037,274
	Accounts receivable from related parties			1,269,092			960,137			815,748			1,643,394			4,073,975			-8,609,228			153,118
	Inventories			-			-			287,625			-			946,790			-137,311			1,097,104
	Prepaid expenses and other current assets			-			71,939			41,240			167			879,085			44,960			1,037,391
	Deferred taxes			-			-			-			-			322,337			-43,285			279,052
		Total current assets		1,269,092			1,032,089			1,301,583			1,643,561			9,777,129			-8,736,738			6,286,716
Property, plant and equipment, net				-			734			238,469			-			2,980,268			-127,517			3,091,954
Intangible assets				-			501			73,166			-			684,290			-81			757,876
Goodwill				-			-			62,829			-			11,595,358			-			11,658,187
Deferred taxes				-			80,931			14,209			-			118,306			-109,279			104,167
Other assets and notes receivables (1)				-			13,955,933			47,661			12,583,487			5,234,132			-30,600,207			1,221,006
	Total assets		$	1,269,092		$	15,070,188		$	1,737,917		$	14,227,048		$	30,389,483		$	-39,573,822		$	23,119,906
Current liabilities:
	Accounts payable		$	-		$	2,193		$	28,689		$	-		$	511,715		$	-		$	542,597
	Accounts payable to related parties			-			1,896,712			522,719			1,600,480			4,931,344			-8,827,326			123,929
	Accrued expenses and other current liabilities			29,770			45,897			129,727			9,403			1,786,709			11,027			2,012,533
	Short-term borrowings			-			60			-			-			96,588			-			96,648
	Short-term borrowings from related parties			-			-			-			-			62,342			-			62,342
	Current portion of long-term debt and capital lease obligations			-			271,090			-			200,000			40,280			-			511,370
	Income tax payable			-			114,197			-			-			56,163			-			170,360
	Deferred taxes			-			2,331			9,002			-			64,539			-41,678			34,194
		Total current liabilities		29,770			2,332,480			690,137			1,809,883			7,549,680			-8,857,977			3,553,973
Long term debt and capital lease obligations, less current portion				1,167,466			96,699			-			2,438,189			7,478,944			-3,434,378			7,746,920
Long term borrowings from related parties				-			3,359,606			-			2,092,818			6,940			-5,459,364			-
Other liabilities				-			5,616			6,028			-			298,313			19,604			329,561
Pension liabilities				-			10,377			254,233			-			171,248			-			435,858
Income tax payable				2,287			30,846			-			-			20,262			123,538			176,933
Deferred taxes				-			-			-			-			768,156			-24,766			743,390
		Total liabilities		1,199,523			5,835,624			950,398			6,340,890			16,293,543			-17,633,343			12,986,635
Noncontrolling interests subject to put provisions				-			-			0			-			648,251			-			648,251
Redeemable Preferred Stock				-			-			-			235,141			-235,141			-			-
Total FMC-AG & Co. KGaA shareholders' equity				69,569			9,234,564			787,519			7,651,017			13,432,374			-21,940,479			9,234,564
Noncontrolling interests not subject to put provisions				-			-			-			-			250,456			-			250,456
Total equity				69,569			9,234,564			787,519			7,651,017			13,682,830			-21,940,479			9,485,020
	Total liabilities and equity		$	1,269,092		$	15,070,188		$	1,737,917		$	14,227,048		$	30,389,483		$	-39,573,822		$	23,119,906
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				For the six months ended June 30, 2014
				Issuer			Guarantors
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
Operating Activities:
	Net income (loss)			$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-746,093		$	527,926
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-315,283			-			-374,253			-			689,536			-
		Depreciation and amortization			-			340			26,497			-			327,154			-17,865			336,126
		Change in deferred taxes, net			-			-10,662			411			-			19,178			-8,235			692
		(Gain) loss on sale of fixed assets and investments			-			-			-107			-			1,651			-			1,544
		(Write Up) write-off loans from related parties			-			54,541			-			-			-			-54,541			-
		Compensation expense related to stock options			-			-1,403			-			-			-			-			-1,403
		Investments in equity method investees, net			-			43,411			-			-			-14,674			-			28,737
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			-3,245			-			-90,574			290			-93,529
		Inventories			-			-			-29,910			-			-181,345			31,157			-180,098
		Prepaid expenses and other current and non-current assets			-			34,643			-14,866			-21,933			-59,782			-4,804			-66,742
		Accounts receivable from / payable to related parties			-406			-169,605			218,846			28,110			-75,880			13,122			14,187
		Accounts payable, accrued expenses and other current and non-current liabilities			-			17,335			41,603			-57			-65,393			-1,139			-7,651
		Income tax payable			-1,707			4,497			-			-26,207			16,137			9,098			1,818
			Net cash provided by (used in) operating activities		75			96,918			242,374			-60,311			372,025			-89,474			561,607
Investing Activities:
	Purchases of property, plant and equipment				-			-37			-43,687			-			-394,161			18,626			-419,259
	Proceeds from sale of property, plant and equipment				-			-			188			-			4,103			-			4,291
	Disbursement of loans to related parties				-			-194,357			-			101,745			-			92,612			-
	Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-197,807			-11,372			-			-434,570			209,052			-434,697
	Proceeds from divestitures				-			-			-			-			3,310			-			3,310
			Net cash provided by (used in) investing activities		-			-392,201			-54,871			101,745			-821,318			320,290			-846,355
Financing Activities:
	Short-term borrowings, net				-			226,862			-183,906			-			145,323			-			188,279
	Long-term debt and capital lease obligations, net				-75			351,059			-			-41,434			119,027			-92,612			335,965
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			72,000			-			72,000
	Proceeds from exercise of stock options				-			37,604			-			-			3,149			-			40,753
	Dividends paid				-			-317,903			-			-			-			-			-317,903
	Capital increase (decrease)				-			-			-			-			142,957			-142,957			-
	Distributions to noncontrolling interest				-			-			-			-			-97,047			-			-97,047
	Contributions from noncontrolling interest				-			-			-			-			25,323			-			25,323
			Net cash provided by (used in) financing activities		-75			297,622			-183,906			-41,434			410,732			-235,569			247,370
Effect of exchange rate changes on cash and cash equivalents					-			259			-54			-			-1,066			-			-861
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					0			2,598			3,543			-			-39,627			-4,753			-38,239
Cash and cash equivalents at beginning of period					0			13			4,490			-			672,206			6,068			682,777
Cash and cash equivalents at end of period				$	0		$	2,611		$	8,033		$	-		$	632,579		$	1,315		$	644,538
				For the six months ended June 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
Operating Activities:
	Net income (loss)			$	2,177		$	488,023		$	-5,310		$	357,133		$	559,265		$	-843,630		$	557,658
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-331,592			-			-432,819			49,662			714,749			-
		Depreciation and amortization			-			330			24,691			-			305,236			-15,103			315,154
		Change in deferred taxes, net			-			-19,248			3,651			-			24,404			-9,336			-529
		(Gain) loss on sale of fixed assets and investments			-			-12			-153			-			-6,089			-			-6,254
		Compensation expense related to stock options			-			12,777			-			-			-			-			12,777
		Cash inflow (outflow) from hedging			-			-4,028			-			-			-			-			-4,028
		Investments in equity method investees, net			-			22,691			-			-			-7,940			-			14,751
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			-11,574			-			-51,000			-			-62,574
		Inventories			-			-			-24,736			-			-29,542			20,013			-34,265
		Prepaid expenses and other current and non-current assets			-			10,768			-17,389			40,202			-39,431			28,585			22,735
		Accounts receivable from / payable to related parties			-410			286,966			68,660			57,847			-462,322			70,579			21,320
		Accounts payable, accrued expenses and other current and non-current liabilities			-			10,171			38,199			106			-53,631			-3,854			-9,009
		Income tax payable			520			729			-			-49,312			35,551			25,313			12,801
			Net cash provided by (used in) operating activities		2,287			477,575			76,039			-26,843			324,163			-12,684			840,537
Investing Activities:
	Purchases of property, plant and equipment				-			-45			-39,394			-			-311,089			16,886			-333,642
	Proceeds from sale of property, plant and equipment				-			17			271			-			14,508			-			14,796
	Disbursement of loans to related parties				-			45,738			-			28,419			-			-74,157			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-23,076			-1,943			-			-100,883			24,093			-101,809
	Proceeds from divestitures				-			-			-			-			17,824			-			17,824
	Net cash provided by (used in) investing activities				-			22,634			-41,066			28,419			-379,640			-33,178			-402,831
Financing Activities:
	Short-term borrowings, net				-			4			-34,873			-			35,808			-			939
	Long-term debt and capital lease obligations, net				-2,287			354			-			1,697,512			-1,736,452			74,157			33,284
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			23,000			-			23,000
	Proceeds from exercise of stock options				-			32,210			-			-			3,932			-			36,142
	Purchase of treasury stock				-			-230,654			-			-			-			-			-230,654
	Dividends paid				-			-296,134			-			-684,229			682,564			1,665			-296,134
	Capital increase (decrease)				-			-			-			-1,014,859			1,016,261			-1,402			-
	Distributions to noncontrolling interest				-			-			-			-			-117,855			-			-117,855
	Contributions from noncontrolling interest				-			-			-			-			27,157			-			27,157
	Net cash provided by (used in) financing activities				-2,287			-494,220			-34,873			-1,576			-65,585			74,420			-524,121
Effect of exchange rate changes on cash and cash equivalents					-			-1,135			-6			-			-14,627			-			-15,768
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					0			4,854			94			-			-135,689			28,558			-102,183
Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
Cash and cash equivalents at end of period				$	1		$	4,932		$	595		$	-		$	550,768		$	29,561		$	585,857

Subsequent_Events

Subsequent Events	3 Months Ended
	Jun. 30, 2014
Notes to Consolidated Financial Statements [Abstract]	'
subsequent event	'
	On July 1, 2014 the Company increased the 2012 Credit Agreement by establishing an incremental term loan tranche of $600,000 ("Term Loan A-2") to finance an investment in the U.S. into Sound Inpatient Physicians, Inc., which closed in July of 2014, and for general corporate purposes. This investment of approximately $550,000 net in Sound Inpatient Physicians, Inc., a physician services organization focused on hospitalist and post-acute care services, furthers the Company's strategic investments in Care Coordination.
	Term Loan A-2 has a one year maturity and must be mandatorily prepaid with 100% of the net cash proceeds of US$-denominated bonds or syndicated term loans, to the extent that these proceeds exceed a certain threshold. The interest rate under the Term Loan A-2 is a rate equal to either (i) Libor plus an applicable margin or (ii) the Base Rate as defined in the 2012 Credit Agreement plus an applicable margin. The applicable margin increases after 90 days and 180 days following disbursement.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Jun. 30, 2014
Inventories (Tables) [Abstract]	'
Inventory Disclosure Tables [Text Block]	'
				30-Jun-14		31-Dec-13
	Finished goods		$	807,525	$	640,355
	Health care supplies			197,596		195,519
	Raw materials and purchased components			195,780		185,146
	Work in process			78,526		76,084
		Inventories	$	1,279,427	$	1,097,104

Longterm_Debt_and_Capital_Leas1

Long-term Debt and Capital Lease Obligations (Tables)	3 Months Ended
	Jun. 30, 2014
Long Term Debt and Capital Lease Obligations (Tables) [Abstract]	'
Schedule of long-term debt	'
			Maximum Amount Available(1)			Balance Outstanding
		30-Jun-14		31-Dec-13		30-Jun-14		31-Dec-13
	Accounts Receivable Facility	$	800,000	$	800,000	$	423,250	$	351,250
	(1) Subject to availability of sufficient accounts receivable meeting funding criteria.
2006 Senior Credit Agreement Table	'
		Maximum Amount Available June 30, 2014				Balance Outstanding June 30, 2014
	Revolving Credit USD	$	600,000	$	600,000	$	235,447	$	235,447
	Revolving Credit EUR	€	500,000	$	682,900	€	463,000	$	632,365
	Term Loan A	$	2,400,000	$	2,400,000	$	2,400,000	$	2,400,000
				$	3,682,900			$	3,267,812
		Maximum Amount Available December 31, 2013				Balance Outstanding December 31, 2013
	Revolving Credit USD	$	600,000	$	600,000	$	138,190	$	138,190
	Revolving Credit EUR	€	500,000	$	689,550	€	50,000	$	68,955
	Term Loan A	$	2,500,000	$	2,500,000	$	2,500,000	$	2,500,000
				$	3,789,550			$	2,707,145

Earning_Per_Share_Tables

Earning Per Share (Tables)	3 Months Ended
	Jun. 30, 2014
Earnings Per Share (Tables) [Abstract]	'
Schedule of Earning per Share	'
		For the three months ended June 30,				For the six months ended June 30,
		2014		2013		2014		2013
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA	$	233,642	$	262,524	$	439,104	$	488,023
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding		301,781,895		302,409,369		301,637,274		302,590,288
	Preference shares outstanding(1)		-		3,842,900		-		3,907,756
	Total weighted average shares outstanding		301,781,895		306,252,269		301,637,274		306,498,044
	Potentially dilutive Ordinary shares		615,485		1,362,863		673,158		1,247,741
	Total weighted average Ordinary shares outstanding assuming dilution		302,397,380		303,772,232		302,310,432		303,838,029
	Basic earnings per share	$	0.77	$	0.86	$	1.46	$	1.59
	Fully diluted earnings per share		0.77		0.85		1.45		1.59
	(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding.

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	3 Months Ended
	Jun. 30, 2014
Employee Benefit Plans (Tables) [Abstract]	'
Schedule of the components of net periodic benefit cost	'
		For the three months ended June 30,				For the six months ended June 30,
		2014		2013		2014		2013
	Components of net periodic benefit cost:
	Service cost	$	4,743	$	3,879	$	9,482	$	7,792
	Interest cost		7,408		6,758		14,812		13,542
	Expected return on plan assets		-3,925		-3,400		-7,850		-6,800
	Amortization of unrealized losses		4,355		6,390		8,709		12,788
	Net periodic benefit costs	$	12,581	$	13,627	$	25,153	$	27,322

Noncontrolling_Interests_Subje1

Noncontrolling Interests Subject To Put Provisions (Tables)	3 Months Ended
	Jun. 30, 2014
Noncontrolling Interests Subject To Put Provisions (Tables) [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	9. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At June 30, 2014 and December 31, 2013, the Company's potential obligations under these put options were $672,234 and $648,251, respectively, of which, at June 30, 2014, put options with an aggregate purchase obligation of $272,417 were exercisable. No put options were exercised during the first six months of 2014.
	The following is a roll forward of noncontrolling interests subject to put provisions for the six months ended June 30, 2014 and the year ended December 31, 2013:
		30-Jun-14		31-Dec-13
	Beginning balance as of January 1,	$	648,251	$	523,260
	Contributions to noncontrolling interests		-60,761		-122,179
	Purchase/ sale of noncontrolling interests		-945		6,723
	Contributions from noncontrolling interests		10,954		17,767
	Changes in fair value of noncontrolling interests		16,409		108,575
	Net income		58,496		113,156
	Other comprehensive income (loss)		-170		949
	Ending balance as of June 30, 2014 and December 31, 2013	$	672,234	$	648,251

Patient_Service_Revenue_Tables

Patient Service Revenue (Tables)	3 Months Ended
	Jun. 30, 2014
Patient Service Revenue by Payor (Abstract)	'
Patient Service Revenue [Text Block]	'
		For the six months ended June 30,
			2014		2013
	Medicare ESRD program	$	2,208,586	$	2,131,095
	Private/alternative payors		2,013,357		1,865,556
	Medicaid and other government sources		202,892		186,059
	Hospitals		220,201		209,517
	Total patient service revenue	$	4,645,036	$	4,392,227

Financial_Instrument_Tables

Financial Instrument (Tables)	3 Months Ended
	Jun. 30, 2014
Financial Instruments (Tables) [Abstract]	'
Non-Derivative Financial Instruments	'
						June 30,						December 31,
						2014						2013
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	644,538			644,538		$	682,777			682,777
		Accounts Receivable(1)	2			3,378,194			3,378,194			3,190,392			3,190,392
		Notes Receivable	3			177,018			192,672			165,807			175,768
	Liabilities
		Accounts payable(1)	2			723,530			723,530			666,526			666,526
		Short-term borrowings(1)	2			359,788			359,788			158,990			158,990
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			663,914			663,914			679,847			679,847
		2012 Credit Agreement	2			3,267,812			3,264,812			2,707,145			2,710,270
		Senior Notes	2			4,809,561			5,396,239			4,824,753			5,348,679
		Euro Notes	2			38,413			39,041			46,545			47,423
	Noncontrolling interests subject to put provisions		3			672,234			672,234			648,251			648,251
	(1) Also includes amounts receivable from or payable to related parties.
Derivative Financial Instruments Valuation	'
				30-Jun-14						31-Dec-13
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		2,235			-3,936			4,985			-2,719
		Non-current
			Foreign exchange contracts		-			-			759			-374
			Interest rate contracts		-			-4,720			-			-4,392
	Total			$	2,235		$	-8,656		$	5,744		$	-7,485
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		4,579			-12,714			11,679			-22,982
		Non-current
			Foreign exchange contracts		308			-744			1,060			-820
	Total			$	4,887		$	-13,458		$	12,739		$	-23,802
	(1) At June 30, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
Effect of Derivatives on the Consolidated Financial Statements	'
				Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
	Derivatives in Cash Flow Hedging Relationships
				(Effective Portion)										(Effective Portion)
				for the six months ended June 30,										for the six months ended June 30,
				2014			2013		(Effective Portion)				2014			2013
	Interest rate contracts		$	1,279		$	3,585		Interest income/expense			$	14,680		$	13,094
	Foreign exchange contracts			-4,224			1,962		Costs of Revenue				2,295			514
	Foreign exchange contracts								Interest income/expense				-			735
			$	-2,945		$	5,547					$	16,975		$	14,343
	Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives
				Location of (Gain) or Loss Recognized in Income on Derivative
							for the six months ended June 30,
							2014			2013
	Foreign exchange contracts			Selling, general and administrative expense		$	5,410		$	-42,134
	Foreign exchange contracts			Interest income/expense			4,219			3,397
						$	9,629		$	-38,737

Other_Comprehensive_Income_Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Jun. 30, 2014
Other Comprehensive Income (Tables) [Abstract]	'
Other Comprehensive Income Rollforward [Text Block]	'
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (Loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		4,902			-			-125,052		-120,150		-2,318		-122,468
		Amounts reclassified from AOCI		9,974			7,885			-		17,859		-		17,859
	Other comprehensive income (loss) after reclassifications			14,876			7,885			-125,052		-102,291		-2,318		-104,609
	Balance at June 30, 2013		$	-123,465		$	-171,538		$	-299,401	$	-594,404	$	551	$	-593,853
	Balance at December 31, 2013		$	-121,856		$	-141,987		$	-286,744	$	-550,587	$	825	$	-549,762
		Other comprehensive income (loss) before reclassifications		-2,057			-			-9,535		-11,592		249		-11,343
		Amounts reclassified from AOCI		12,146			5,489			-		17,635		-		17,635
	Other comprehensive income (loss) after reclassifications			10,089			5,489			-9,535		6,043		249		6,292
	Balance at June 30, 2014		$	-111,767		$	-136,498		$	-296,279	$	-544,544	$	1,074	$	-543,470
Other Comprehensive Income Reclassifications [Text Block]	'
	Details about AOCI Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the six months ended June 30,
				2014			2013
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	14,680		$	13,094		Interest income/expense
		Foreign exchange contracts			2,295			514		Costs of Revenue
		Foreign exchange contracts			-			735		Interest income/expense
					16,975			14,343		Total before tax
					-4,829			-4,369		Tax expense or benefit
				$	12,146		$	9,974		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) loss			8,709			12,788		-1
					8,709			12,788		Total before tax
					-3,220			-4,903		Tax expense or benefit
				$	5,489		$	7,885		Net of tax
	Total reclassifications for the period			$	17,635		$	17,859		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 8 for additional details).

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Jun. 30, 2014
Business Segment Information (Tables) [Abstract]	'
Schedule of segment reporting information by segment	'
					North America Segment		International Segment		Segment Totals		Corporate		Total
	Three months ended June 30, 2014
		Net revenue external customers		$	2,520,988	$	1,296,620	$	3,817,608	$	17,194	$	3,834,802
		Inter - segment revenue			2,269		-		2,269		-2,269		-
		Revenue			2,523,257		1,296,620		3,819,877		14,925		3,834,802
		Depreciation and amortization			-87,173		-46,312		-133,485		-35,474		-168,959
		Operating income			400,714		243,009		643,723		-87,450		556,273
		Income (loss) from equity method investees			3,818		2,151		5,969		-		5,969
		Capital expenditures, acquisitions and investments			283,350		180,734		464,084		53,084		517,168
	Three months ended June 30, 2013
		Net revenue external customers		$	2,375,247	$	1,228,322	$	3,603,569	$	8,946	$	3,612,515
		Inter - segment revenue			1,771		-		1,771		-1,771		-
		Revenue			2,377,018		1,228,322		3,605,340		7,175		3,612,515
		Depreciation and amortization(1)			-81,466		-46,432		-127,898		-30,903		-158,801
		Operating income (2)			390,655		218,479		609,134		-64,895		544,239
		Income (loss) from equity method investees(3)			2,871		1,545		4,416		-		4,416
		Capital expenditures, acquisitions and investments			107,948		66,175		174,123		41,757		215,880
	Six months ended June 30, 2014
		Net revenue external customers		$	4,913,894	$	2,457,517	$	7,371,411	$	26,983	$	7,398,394
		Inter - segment revenue			3,549		-		3,549		-3,549		-
		Revenue			4,917,443		2,457,517		7,374,960		23,434		7,398,394
		Depreciation and amortization			-174,822		-91,333		-266,155		-69,971		-336,126
		Operating Income			736,276		423,455		1,159,731		-158,563		1,001,168
		Income (loss) from equity method investees			14,368		4,123		18,491		-		18,491
		Segment assets			15,060,591		6,761,277		21,821,868		2,323,389		24,145,257
			thereof investments in equity method investees		306,313		431,603		737,916		-		737,916
		Capital expenditures, acquisitions and investments(4)			488,249		245,371		733,620		120,336		853,956
	Six months ended June 30, 2013
		Net revenue external customers		$	4,662,497	$	2,396,974	$	7,059,471	$	16,965	$	7,076,436
		Inter - segment revenue			2,846		-		2,846		-2,846		-
		Revenue			4,665,343		2,396,974		7,062,317		14,119		7,076,436
		Depreciation and amortization(1)			-161,873		-92,332		-254,205		-60,949		-315,154
		Operating Income(2)			756,703		410,096		1,166,799		-129,247		1,037,552
		Income (loss) from equity method investees(3)			5,989		3,235		9,224		-		9,224
		Segment assets			14,094,573		5,971,984		20,066,557		2,261,790		22,328,347
			thereof investments in equity method investees		247,277		370,153		617,430		-		617,430
		Capital expenditures, acquisitions and investments(4)			220,280		148,877		369,157		66,294		435,451
		(1) Depreciation in the amount of $988 and $1,884 for the three and six months ended June 30, 2013, respectively, relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(2) Certain items, in the net aggregate amount of $6,364 and $11,370 for the three and six months ended June 30, 2013, respectively, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable.
		(3) Income (loss) from equity method investees in the amount of $717 and $321 for the three and six months ended June 30, 2013, respectively, has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(4) International acquisitions exclude $167,905 and $11,684 of non-cash acquisitions for 2014 and 2013, respectively.

Supplementary_Cash_Flow_Inform1

Supplementary Cash Flow Information (Tables)	3 Months Ended
	Jun. 30, 2014
Supplementary Cash Flow Information (Tables) [Abstract]	'
Schedule of supplemental Cash Flow information	'
			For the six months ended June 30,
			2014		2013
	Supplementary cash flow information:
		Cash paid for interest	$	189,038	$	191,259
		Cash paid for income taxes (1)	$	304,785	$	225,740
		Cash inflow for income taxes from stock option exercises	$	3,153	$	3,933
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-523,912	$	-130,864
		Liabilities assumed		241,132		17,173
		Noncontrolling interest subject to put provisions		3,110		15,320
		Noncontrolling interest		6,191		5,570
		Pending payments for purchase considerations		9,156		11,683
		Cash paid		-264,323		-81,118
		Less cash acquired		84,694		5,139
		Net cash paid for acquisitions		-179,629		-75,979
		Cash paid for investments		-249,156		-22,894
		Cash paid for intangible assets		-5,912		-2,936
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-434,697	$	-101,809
		(1) Net of tax refund.

Supplemental_Condensed_Combini1

Supplemental Condensed Combining Information (Tables)	3 Months Ended
	Jun. 30, 2014
Supplemental Condensed Combining Information (Tables) [Abstract]	'
Income statement information segregated by issuers and guarantors	'
			For the six months ended June 30, 2014
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,092,279		$	-		$	8,085,343		$	-1,779,228		$	7,398,394
	Cost of revenue			-			-			691,930			-			6,160,749			-1,747,835			5,104,844
		Gross profit		-			-			400,349			-			1,924,594			-31,393			2,293,550
	Operating expenses (income):
		Selling, general and administrative(1)		-			83,548			84,853			-24,234			1,074,154			13,332			1,231,653
		Research and development		-			-			38,761			-			21,968			-			60,729
	Operating (loss) income			-			-83,548			276,735			24,234			828,472			-44,725			1,001,168
	Other (income) expense:
		Interest, net		-3,461			122,940			-2,928			90,665			-12,549			-			194,667
		Other, net		-			-671,761			202,485			-374,253			-			843,529			-
	Income (loss) before income taxes			3,461			465,273			77,178			307,822			841,021			-888,254			806,501
		Income tax expense (benefit)		1,273			26,169			74,033			-26,207			345,468			-142,161			278,575
	Net Income (loss)			2,188			439,104			3,145			334,029			495,553			-746,093			527,926
	Net Income attributable to noncontrolling interests			-			-			-			-			-			88,822			88,822
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-834,915		$	439,104
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the six months ended June 30, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	1,006,662		$	-		$	7,664,410		$	-1,594,636		$	7,076,436
	Cost of revenue			-			-			663,055			-			5,719,837			-1,574,347			4,808,545
		Gross profit		-			-			343,607			-			1,944,573			-20,289			2,267,891
	Operating expenses (income):
		Selling, general and administrative (1)		-			40,547			106,983			37,920			964,028			19,568			1,169,046
		Research and development		-			-			36,549			-			24,912			-168			61,293
	Operating (loss) income			-			-40,547			200,075			-37,920			955,633			-39,689			1,037,552
	Other (income) expense:
		Interest, net		-3,417			95,049			3,804			87,078			24,349			417			207,280
		Other, net		-			-615,001			164,333			-432,819			-			883,487			-
	Income (loss) before income taxes			3,417			479,405			31,938			307,821			931,284			-923,593			830,272
		Income tax expense (benefit)		1,240			-8,618			37,248			-49,312			322,357			-30,301			272,614
	Net Income (loss)			2,177			488,023			-5,310			357,133			608,927			-893,292			557,658
	Net Income attributable to noncontrolling interests			-			-			-			-			-			69,635			69,635
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	2,177		$	488,023		$	-5,310		$	357,133		$	608,927		$	-962,927		$	488,023
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
Balance sheet information segregated by issuers and guarantors	'
				At June 30, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	0		$	2,611		$	8,033		$	-		$	632,579		$	1,315		$	644,538
		Trade accounts receivable, less allowance for doubtful accounts			-			-			154,243			-			3,020,417			1,750			3,176,410
		Accounts receivable from related parties			1,267,108			1,351,662			1,040,410			1,654,545			4,297,558			-9,409,499			201,784
		Inventories			-			-			314,662			-			1,129,355			-164,590			1,279,427
		Prepaid expenses and other current assets			-			49,754			56,457			67			1,090,101			51,854			1,248,233
		Deferred taxes			-			-			-			-			299,458			-44,690			254,768
			Total current assets		1,267,108			1,404,027			1,573,805			1,654,612			10,469,468			-9,563,860			6,805,160
	Property, plant and equipment, net				-			651			257,430			-			3,168,807			-127,008			3,299,880
	Intangible assets				-			270			68,318			-			659,594			-89			728,093
	Goodwill				-			-			62,223			-			11,811,766			-			11,873,989
	Deferred taxes				-			85,060			14,829			-			128,624			-111,052			117,461
	Other assets and notes receivables(1)				-			14,258,249			57,611			12,894,961			5,068,002			-30,958,149			1,320,674
		Total assets		$	1,267,108		$	15,748,257		$	2,034,216		$	14,549,573		$	31,306,261		$	-40,760,158		$	24,145,257
	Current liabilities:
		Accounts payable		$	-		$	651		$	32,873		$	-		$	525,507		$	-		$	559,031
		Accounts payable to related parties			-			2,032,970			785,342			1,602,668			5,394,855			-9,651,336			164,499
		Accrued expenses and other current liabilities			29,771			54,308			154,350			9,346			1,802,668			4,240			2,054,683
		Short-term borrowings			-			68,290			-			-			129,514			-			197,804
		Short-term borrowings from related parties			-			-			-			-			161,984			-			161,984
		Current portion of long-term debt and capital lease obligations			-			68,749			-			200,000			66,667			-			335,416
		Income tax payable			-			117,578			-			-			58,684			1,770			178,032
		Deferred taxes			-			1,259			10,598			-			66,651			-43,036			35,472
			Total current liabilities		29,771			2,343,805			983,163			1,812,014			8,206,530			-9,688,362			3,686,921
	Long term debt and capital lease obligations, less current portion				1,165,000			646,406			-			2,435,447			7,390,784			-3,193,353			8,444,284
	Long term borrowings from related parties				-			3,328,094			-			2,076,579			5,985			-5,410,658			-
	Other liabilities				-			5,340			5,644			-			302,918			23,245			337,147
	Pension liabilities				-			12,395			261,351			-			162,965			-			436,711
	Income tax payable				580			30,549			-			-			24,791			129,556			185,476
	Deferred taxes				-			-			-			-			757,995			-25,665			732,330
			Total liabilities		1,195,351			6,366,589			1,250,158			6,324,040			16,851,968			-18,165,237			13,822,869
	Noncontrolling interests subject to put provisions				-			-			0			-			672,234			-			672,234
	Redeemable Preferred Stock				-			-			-			235,141			-235,141			-			-
	Total FMC-AG & Co. KGaA shareholders' equity				71,757			9,381,668			784,058			7,990,392			13,748,714			-22,594,921			9,381,668
	Noncontrolling interests not subject to put provisions				-			-			-			-			268,486			-			268,486
	Total equity				71,757			9,381,668			784,058			7,990,392			14,017,200			-22,594,921			9,650,154
		Total liabilities and equity		$	1,267,108		$	15,748,257		$	2,034,216		$	14,549,573		$	31,306,261		$	-40,760,158		$	24,145,257
	(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				At December 31, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	0		$	13		$	4,490		$	-		$	672,206		$	6,068		$	682,777
		Trade accounts receivable, less allowance for doubtful accounts			-			-			152,480			-			2,882,736			2,058			3,037,274
		Accounts receivable from related parties			1,269,092			960,137			815,748			1,643,394			4,073,975			-8,609,228			153,118
		Inventories			-			-			287,625			-			946,790			-137,311			1,097,104
		Prepaid expenses and other current assets			-			71,939			41,240			167			879,085			44,960			1,037,391
		Deferred taxes			-			-			-			-			322,337			-43,285			279,052
			Total current assets		1,269,092			1,032,089			1,301,583			1,643,561			9,777,129			-8,736,738			6,286,716
	Property, plant and equipment, net				-			734			238,469			-			2,980,268			-127,517			3,091,954
	Intangible assets				-			501			73,166			-			684,290			-81			757,876
	Goodwill				-			-			62,829			-			11,595,358			-			11,658,187
	Deferred taxes				-			80,931			14,209			-			118,306			-109,279			104,167
	Other assets and notes receivables (1)				-			13,955,933			47,661			12,583,487			5,234,132			-30,600,207			1,221,006
		Total assets		$	1,269,092		$	15,070,188		$	1,737,917		$	14,227,048		$	30,389,483		$	-39,573,822		$	23,119,906
	Current liabilities:
		Accounts payable		$	-		$	2,193		$	28,689		$	-		$	511,715		$	-		$	542,597
		Accounts payable to related parties			-			1,896,712			522,719			1,600,480			4,931,344			-8,827,326			123,929
		Accrued expenses and other current liabilities			29,770			45,897			129,727			9,403			1,786,709			11,027			2,012,533
		Short-term borrowings			-			60			-			-			96,588			-			96,648
	Short-term borrowings from related parties			-			-			-			-			62,342			-			62,342
	Current portion of long-term debt and capital lease obligations			-			271,090			-			200,000			40,280			-			511,370
	Income tax payable			-			114,197			-			-			56,163			-			170,360
	Deferred taxes			-			2,331			9,002			-			64,539			-41,678			34,194
		Total current liabilities		29,770			2,332,480			690,137			1,809,883			7,549,680			-8,857,977			3,553,973
Long term debt and capital lease obligations, less current portion				1,167,466			96,699			-			2,438,189			7,478,944			-3,434,378			7,746,920
Long term borrowings from related parties				-			3,359,606			-			2,092,818			6,940			-5,459,364			-
Other liabilities				-			5,616			6,028			-			298,313			19,604			329,561
Pension liabilities				-			10,377			254,233			-			171,248			-			435,858
Income tax payable				2,287			30,846			-			-			20,262			123,538			176,933
Deferred taxes				-			-			-			-			768,156			-24,766			743,390
		Total liabilities		1,199,523			5,835,624			950,398			6,340,890			16,293,543			-17,633,343			12,986,635
Noncontrolling interests subject to put provisions				-			-			0			-			648,251			-			648,251
Redeemable Preferred Stock				-			-			-			235,141			-235,141			-			-
Total FMC-AG & Co. KGaA shareholders' equity				69,569			9,234,564			787,519			7,651,017			13,432,374			-21,940,479			9,234,564
Noncontrolling interests not subject to put provisions				-			-			-			-			250,456			-			250,456
Total equity				69,569			9,234,564			787,519			7,651,017			13,682,830			-21,940,479			9,485,020
	Total liabilities and equity		$	1,269,092		$	15,070,188		$	1,737,917		$	14,227,048		$	30,389,483		$	-39,573,822		$	23,119,906
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
Statement of cash flows information segregated by issuers and guarantors	'
					For the six months ended June 30, 2014
					Issuer			Guarantors
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Operating Activities:
		Net income (loss)			$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-746,093		$	527,926
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-315,283			-			-374,253			-			689,536			-
			Depreciation and amortization			-			340			26,497			-			327,154			-17,865			336,126
			Change in deferred taxes, net			-			-10,662			411			-			19,178			-8,235			692
			(Gain) loss on sale of fixed assets and investments			-			-			-107			-			1,651			-			1,544
			(Write Up) write-off loans from related parties			-			54,541			-			-			-			-54,541			-
			Compensation expense related to stock options			-			-1,403			-			-			-			-			-1,403
			Investments in equity method investees, net			-			43,411			-			-			-14,674			-			28,737
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			-3,245			-			-90,574			290			-93,529
			Inventories			-			-			-29,910			-			-181,345			31,157			-180,098
			Prepaid expenses and other current and non-current assets			-			34,643			-14,866			-21,933			-59,782			-4,804			-66,742
			Accounts receivable from / payable to related parties			-406			-169,605			218,846			28,110			-75,880			13,122			14,187
			Accounts payable, accrued expenses and other current and non-current liabilities			-			17,335			41,603			-57			-65,393			-1,139			-7,651
			Income tax payable			-1,707			4,497			-			-26,207			16,137			9,098			1,818
				Net cash provided by (used in) operating activities		75			96,918			242,374			-60,311			372,025			-89,474			561,607
	Investing Activities:
		Purchases of property, plant and equipment				-			-37			-43,687			-			-394,161			18,626			-419,259
		Proceeds from sale of property, plant and equipment				-			-			188			-			4,103			-			4,291
		Disbursement of loans to related parties				-			-194,357			-			101,745			-			92,612			-
		Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-197,807			-11,372			-			-434,570			209,052			-434,697
		Proceeds from divestitures				-			-			-			-			3,310			-			3,310
				Net cash provided by (used in) investing activities		-			-392,201			-54,871			101,745			-821,318			320,290			-846,355
	Financing Activities:
		Short-term borrowings, net				-			226,862			-183,906			-			145,323			-			188,279
		Long-term debt and capital lease obligations, net				-75			351,059			-			-41,434			119,027			-92,612			335,965
		Increase (decrease) of accounts receivable securitization program				-			-			-			-			72,000			-			72,000
		Proceeds from exercise of stock options				-			37,604			-			-			3,149			-			40,753
		Dividends paid				-			-317,903			-			-			-			-			-317,903
		Capital increase (decrease)				-			-			-			-			142,957			-142,957			-
		Distributions to noncontrolling interest				-			-			-			-			-97,047			-			-97,047
		Contributions from noncontrolling interest				-			-			-			-			25,323			-			25,323
				Net cash provided by (used in) financing activities		-75			297,622			-183,906			-41,434			410,732			-235,569			247,370
	Effect of exchange rate changes on cash and cash equivalents					-			259			-54			-			-1,066			-			-861
	Cash and Cash Equivalents:
	Net increase (decrease) in cash and cash equivalents					0			2,598			3,543			-			-39,627			-4,753			-38,239
	Cash and cash equivalents at beginning of period					0			13			4,490			-			672,206			6,068			682,777
	Cash and cash equivalents at end of period				$	0		$	2,611		$	8,033		$	-		$	632,579		$	1,315		$	644,538
					For the six months ended June 30, 2013
					Issuer			Guarantors									Non-Guarantor Subsidiaries
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
	Operating Activities:
		Net income (loss)			$	2,177		$	488,023		$	-5,310		$	357,133		$	559,265		$	-843,630		$	557,658
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-331,592			-			-432,819			49,662			714,749			-
			Depreciation and amortization			-			330			24,691			-			305,236			-15,103			315,154
			Change in deferred taxes, net			-			-19,248			3,651			-			24,404			-9,336			-529
			(Gain) loss on sale of fixed assets and investments			-			-12			-153			-			-6,089			-			-6,254
			Compensation expense related to stock options			-			12,777			-			-			-			-			12,777
			Cash inflow (outflow) from hedging			-			-4,028			-			-			-			-			-4,028
			Investments in equity method investees, net			-			22,691			-			-			-7,940			-			14,751
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			-11,574			-			-51,000			-			-62,574
			Inventories			-			-			-24,736			-			-29,542			20,013			-34,265
			Prepaid expenses and other current and non-current assets			-			10,768			-17,389			40,202			-39,431			28,585			22,735
			Accounts receivable from / payable to related parties			-410			286,966			68,660			57,847			-462,322			70,579			21,320
			Accounts payable, accrued expenses and other current and non-current liabilities			-			10,171			38,199			106			-53,631			-3,854			-9,009
			Income tax payable			520			729			-			-49,312			35,551			25,313			12,801
			Net cash provided by (used in) operating activities		2,287			477,575			76,039			-26,843			324,163			-12,684			840,537
Investing Activities:
	Purchases of property, plant and equipment				-			-45			-39,394			-			-311,089			16,886			-333,642
	Proceeds from sale of property, plant and equipment				-			17			271			-			14,508			-			14,796
	Disbursement of loans to related parties				-			45,738			-			28,419			-			-74,157			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-23,076			-1,943			-			-100,883			24,093			-101,809
	Proceeds from divestitures				-			-			-			-			17,824			-			17,824
	Net cash provided by (used in) investing activities				-			22,634			-41,066			28,419			-379,640			-33,178			-402,831
Financing Activities:
	Short-term borrowings, net				-			4			-34,873			-			35,808			-			939
	Long-term debt and capital lease obligations, net				-2,287			354			-			1,697,512			-1,736,452			74,157			33,284
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			23,000			-			23,000
	Proceeds from exercise of stock options				-			32,210			-			-			3,932			-			36,142
	Purchase of treasury stock				-			-230,654			-			-			-			-			-230,654
	Dividends paid				-			-296,134			-			-684,229			682,564			1,665			-296,134
	Capital increase (decrease)				-			-			-			-1,014,859			1,016,261			-1,402			-
	Distributions to noncontrolling interest				-			-			-			-			-117,855			-			-117,855
	Contributions from noncontrolling interest				-			-			-			-			27,157			-			27,157
	Net cash provided by (used in) financing activities				-2,287			-494,220			-34,873			-1,576			-65,585			74,420			-524,121
Effect of exchange rate changes on cash and cash equivalents					-			-1,135			-6			-			-14,627			-			-15,768
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					0			4,854			94			-			-135,689			28,558			-102,183
Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
Cash and cash equivalents at end of period				$	1		$	4,932		$	595		$	-		$	550,768		$	29,561		$	585,857
Other comprehensive income statement segregated by issuers and guarantors	'
				For the six months ended June 30, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	2,188		$	439,104		$	3,145		$	334,029		$	495,553		$	-746,093		$	527,926
		Gain (loss) related to cash flow hedges			-			16,076			-			-			-2,046			-			14,030
		Actuarial gain (loss) on defined benefit pension plans			-			99			1,894			6,524			192			-			8,709
		Gain (loss) related to foreign currency translation			-			36,765			-7,260			-			-38,509			-282			-9,286
		Income tax (expense) benefit related to components of other comprehensive income			-			-4,646			-553			-2,574			612			-			-7,161
	Other comprehensive income (loss), net of tax				-			48,294			-5,919			3,950			-39,751			-282			6,292
	Total comprehensive income			$	2,188		$	487,398		$	-2,774		$	337,979		$	455,802		$	-746,375		$	534,218
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			89,071			89,071
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	2,188		$	487,398		$	-2,774		$	337,979		$	455,802		$	-835,446		$	445,147
				For the six months ended June 30, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	2,177		$	488,023		$	-5,310		$	357,133		$	608,927		$	-893,292		$	557,658
		Gain (loss) related to cash flow hedges			-			14,431			-			-			5,459			-			19,890
		Actuarial gain (loss) on defined benefit pension plans			-			65			1,267			11,335			121			-			12,788
		Gain (loss) related to foreign currency translation			-			27,707			-6,535			-			-154,575			6,033			-127,370
		Income tax (expense) benefit related to components of other comprehensive income			-			-4,162			-369			-4,472			-914			-			-9,917
	Other comprehensive income (loss), net of tax				-			38,041			-5,637			6,863			-149,909			6,033			-104,609
	Total comprehensive income			$	2,177		$	526,064		$	-10,947		$	363,996		$	459,018		$	-887,259		$	453,049
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			67,317			67,317
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	2,177		$	526,064		$	-10,947		$	363,996		$	459,018		$	-954,576		$	385,732

Related_Party_Transactions_Det

Related Party Transactions (Details)

3 Months Ended

6 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Thousands, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

USD ($)

USD ($)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Operating Lease Agreements [Member]

Operating Lease Agreements [Member]

Sales To Related Party [Member]

Sales To Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

accounts payable

accounts payable

accounts receivable

accounts receivable

Accounts Receivable Serices [Member]

Accounts Receivable Serices [Member]

Accounts Payable Serices [Member]

Accounts Payable Serices [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

General Partner [Member]

General Partner [Member]

Equity Method Investees [Member]

Equity Method Investees [Member]

Equity Method Investees [Member]

Equity Method Investees [Member]

Equity Method Investees [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

General partner extensions [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Operating Lease Agreements [Member]

Operating Lease Agreements [Member]

Sales To Related Party [Member]

Sales To Related Party [Member]

Accounts Receivable Serices [Member]

Accounts Payable Serices [Member]

Accounts Payable Serices [Member]

USD ($)

EUR (€)

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Accounts Receivable Serices [Member]

Accounts Receivable Serices [Member]

equity method investee

USD ($)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Operating Lease Agreements [Member]

Operating Lease Agreements [Member]

Sales To Related Party [Member]

Sales To Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

Senior notes held by related party [Member]

Senior notes held by related party [Member]

accounts payable

accounts payable

accounts receivable

accounts receivable

Accounts Receivable Serices [Member]

Accounts Receivable Serices [Member]

Accounts Payable Serices [Member]

Accounts Payable Serices [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Related Party Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of transaction

$1

'

$39,782

$57,253

$14,312

$13,934

$14,256

$13,317

$24,710

$15,598

$23,153

$30,930

$4,546

$7,231

$20,705

$18,587

$4,664

$21,556

$6,718

$4,265

'

'

$11,757

$11,406

$184

$208

$5,299

$4,871

'

$17

$245

$4,253

$2,365

'

'

$9,782

$10,547

$3,999

$20,336

$22,500

'

$28,025

$45,847

$4,346

$3,179

$8,957

$8,446

$24,710

$15,581

$23,153

$30,930

$16,116

€ 11,800

$4,546

$7,231

$20,705

$18,587

$664

$975

$2,465

$1,900

'

Due to related parties

164,499

123,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,049

1,500

'

'

'

'

'

57,515

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.34%

1.34%

'

'

'

'

2.54%

6.10%

'

'

'

'

'

'

'

'

'

'

5.25%

5.25%

'

'

'

'

'

'

'

'

1.88%

Date of repayment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Jul-14

31-Jul-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23-May-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$157,886

€ 115,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate, advances received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.47%

1.47%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories (Details) [Abstract]	'	'
Raw materials and purchased components	$197,596	$195,519
Work in process	78,526	76,084
Finished goods	807,525	640,355
Health care supplies	195,780	185,146
Inventories	$1,279,427	$1,097,104

Other_Assets_and_Notes_Receiva

Other Assets and Notes Receivable (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Accounts notes and loans receivable [LineItems]	'
Borrowings Available Under Notes Receivable	200,000
Notes Receivable Maturity Date	'date of July 4, 2020 (unless prepaid)
Notes Receivable Cash Interest Rate	10.75%
Notes Receivable PIK Interest Rate	11.75%
Notes Receivable Balance	$180,137
Notes Receivable Interest Income	$3,679

Longterm_Debt_and_Capital_Leas2

Long-term Debt and Capital Lease Obligations (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	$4,809,561	$4,824,753
Capital lease obligations	46,861	24,264
Other	193,803	111,259
Long-term debt and capital lease obligations	8,779,700	8,258,290
Less current maturities	335,416	511,370
Total long-term debt less current maturities	8,444,284	7,746,920
Revolving credit maximum amount available	3,682,900	3,789,550
Revolving credit balance outstanding	3,267,812	2,707,145
Accounts receivable facility	423,250	351,250
Senior Credit Agreement 2012 Member [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Credit Agreement	3,267,812	2,707,145
Line of credit outstanding which reduces available borrowings under the revolving credit facility	7,143	9,444
RevolvingCreditUSD [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	600,000	600,000
Revolving credit balance outstanding	235,447	138,190
RevolvingCreditEUR [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	682,900	689,550
Revolving credit balance outstanding	632,365	68,955
TermLoanA2012 [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	2,400,000	2,500,000
Revolving credit balance outstanding	2,400,000	2,500,000
Euro Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	38,413	46,545
EIB Agreements [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	'	193,074
Accounts Receivable Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Maximum amount available	800,000	'
Balance outstanding	'	351,250
Line of credit outstanding which reduces available borrowings under the revolving credit facility	$66,622	'

Recovered_Sheet1

Short-term Borrowings and Other Financial Liabilities and Short-term Borrowings from Related Parties (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Short Term Borrowings Other Financial Liabilities And Short Term Borrowings From Related Parties (Details) [Abstract]	'	'
Borrowings under lines of credit	$197,567	$95,690
Accounts receivable facility	423,250	351,250
Other financial liabilities	237	958
Related Party Transaction [Line Items]	'	'
Related Party Transaction Amounts Of Transaction	1	'
Short-term borrowings and other financial liabilities	197,804	96,648
Short Term Borrowings Due To Related Parties Current Acquisitions	161,984	62,342
Short-term borrowings, Other financial liabilities and Short-term borrowings from related parties	$359,788	$158,990
General Partner [Member]	'	'
Related Party Transaction [Line Items]	'	'
Related Party Transaction Rate	1.34%	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerators:	'	'	'	'
Income attributable to the Company	$233,642,000	$262,524,000	$439,104,000	$488,023,000
Denominators:	'	'	'	'
Weighted average number of ordinary shares outstanding	301,781,895	302,409,369	301,637,274	302,590,288
Weighted average number of preference shares outstanding	0	3,842,900	0	3,907,756
Total weighted average shares outstanding	301,781,895	306,252,269	301,637,274	306,498,044
Potentially dilutive Ordinary shares	615,485	1,362,863	673,158	1,247,741
Total weighted average Ordinary shares outstanding assuming dilution	302,397,380	303,772,232	302,310,432	303,838,029
Basic income per Ordinary share	0.77	0.86	1.46	1.59
Fully diluted income per Ordinary share	$0.77	$0.85	$1.45	$1.59

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Components Of Net Periodic Benefit Cost [Abstract]	'	'	'	'
Service cost	$4,743	$3,879	$9,482	$7,792
Interest cost	7,408	6,758	14,812	13,542
Expected return on plan assets	-3,925	-3,400	-7,850	-6,800
Amortization of unrealized losses	4,355	6,390	8,709	12,788
Net periodic benefit costs	$12,581	$13,627	$25,153	$27,322

Noncontrolling_Interests_Subje2

Noncontrolling Interests Subject to Put Provisions (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Noncontrolling Interests Subject To Put Provisions (Details) [Abstract]	'	'	'	'	'
Potential obligations under the put provisions	$672,234	'	$672,234	'	$648,251
Temporary Equity [Line Items]	'	'	'	'	'
Noncontrolling interests subject to put provisions beginning balance	'	'	648,251	'	'
Dividends paid	317,903	'	'	'	296,134
Noncontrolling interest increase from sale of parent equity interest	3,892	'	'	'	-15,173
Minority interest decrease from distributions to noncontrolling interest holders	-19,660	'	'	'	-32,275
Changes in fair value of noncontrolling interests	-16,409	'	'	'	-108,575
Net Income	280,576	297,575	527,926	557,658	'
Other comprehensive income loss net of tax	45,585	-52,028	6,292	-104,609	'
Noncontrolling interests subject to put provisions ending balance	672,234	'	672,234	'	648,251
Put provisions exercisable	272,417	'	272,417	'	'
Noncontrolling interests subject to put provisions [Member]	'	'	'	'	'
Temporary Equity [Line Items]	'	'	'	'	'
Dividends paid	-60,761	'	'	'	-122,179
Noncontrolling interest increase from sale of parent equity interest	-945	'	'	'	6,723
Minority interest decrease from distributions to noncontrolling interest holders	10,954	'	'	'	17,767
Changes in fair value of noncontrolling interests	16,409	'	'	'	108,575
Net Income	58,496	'	'	'	113,156
Other comprehensive income loss net of tax	-170	'	'	'	949
Noncontrolling interests subject to put provisions ending balance	'	'	'	'	$523,260

Patient_Service_Revenue_Detail

Patient Service Revenue (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$4,645,036	$4,392,227
Medicare ESRD program	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	2,208,586	2,131,095
Hospitals	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	220,201	209,517
Private	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	2,013,357	1,865,556
Medicaid and other government sources	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$202,892	$186,059

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets:	'	'	'	'	'	'
Cash and cash equivalents	$644,538	$644,538	'	$682,777	$682,777	$688,040
Liabilities:	'	'	'	'	'	'
Short-term borrowings	197,804	197,804	'	'	96,648	'
Short-term borrowings from related parties	161,984	161,984	'	'	62,342	'
Senior Long Term Notes	4,809,561	4,809,561	'	'	4,824,753	'
Noncontrolling interests subject to put provisions	672,234	672,234	'	'	648,251	'
Notional amount cash of flow hedge	144,173	144,173	238,983	'	'	'
Notional amount of foreign currency derivative	136,580	136,580	137,910	'	'	'
notional amount of derivative asset	1,562,841	1,562,841	1,512,559	'	'	'
Amount estimated to be transferred in the future from accumulated OCI into earnings	'	107,229	118,844	'	'	'
Amount of additional interest expense expected to be reclassified into earnings	'	867	735	'	'	'
The time period estimated for the anticipated transfer of interest expense into earnings	'12 months	'	'	'	'	'
Derivative assets subject to master netting agreements	7,122	7,122	'	'	18,334	'
Derivative liabilities subject to master netting agreements	19,456	19,456	'	'	16,371	'
Derivative net assets subject to master netting agreements	2,060	2,060	'	'	12,169	'
Derivative net liabiltiies subject to master netting agreements	14,394	14,394	'	'	10,207	'
Euro Notes [Member]	'	'	'	'	'	'
Liabilities:	'	'	'	'	'	'
Senior Long Term Notes	38,413	38,413	'	'	46,545	'
Carrying Reported Amount Fair Value Disclosure [Member]	'	'	'	'	'	'
Assets:	'	'	'	'	'	'
Cash and cash equivalents	644,538	644,538	'	'	682,777	'
Accounts receivable	3,378,194	3,378,194	'	'	3,190,392	'
Long-term notes receivable	177,018	177,018	'	'	165,807	'
Liabilities:	'	'	'	'	'	'
Accounts Payable	723,530	723,530	'	'	666,526	'
Short-term borrowings	359,788	359,788	'	'	158,990	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	663,914	663,914	'	'	679,847	'
Senior Credit Agreement	3,267,812	3,267,812	'	'	2,707,145	'
Senior Long Term Notes	4,809,561	4,809,561	'	'	4,824,753	'
Noncontrolling interests subject to put provisions	672,234	672,234	'	'	648,251	'
Carrying Reported Amount Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'	'	'	'
Liabilities:	'	'	'	'	'	'
Senior Long Term Notes	38,413	38,413	'	'	46,545	'
Portion At Fair Value Fair Value Disclosure [Member]	'	'	'	'	'	'
Assets:	'	'	'	'	'	'
Cash and cash equivalents	644,538	644,538	'	'	682,777	'
Accounts receivable	3,378,194	3,378,194	'	'	3,190,392	'
Long-term notes receivable	192,672	192,672	'	'	175,768	'
Liabilities:	'	'	'	'	'	'
Accounts Payable	723,530	723,530	'	'	666,526	'
Short-term borrowings	359,788	359,788	'	'	158,990	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	663,914	663,914	'	'	679,847	'
Senior Credit Agreement	3,264,812	3,264,812	'	'	2,710,270	'
Senior Long Term Notes	5,396,239	5,396,239	'	'	5,348,679	'
Noncontrolling interests subject to put provisions	672,234	672,234	'	'	648,251	'
Portion At Fair Value Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'	'	'	'
Liabilities:	'	'	'	'	'	'
Senior Long Term Notes	$39,041	$39,041	'	'	$47,423	'

Financial_Instruments_Details_

Financial Instruments (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	$2,235	$5,744
Liabilities	-8,656	-7,485
Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	4,887	12,739
Liabilities	-13,458	-23,802
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member]	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	0	'
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	2,235	4,985
Liabilities	-3,936	-2,719
Foreign Exchange Contract Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	4,579	11,679
Liabilities	-12,714	-22,982
Foreign Exchange Contract Non Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	0	759
Liabilities	'	-374
Foreign Exchange Contract Non Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	308	1,060
Liabilities	-744	-820
Interest Rate Contract Non Current Dollar [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	($4,720)	($4,392)

Financial_Instruments_Details_1

Financial Instruments (Details 2) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Designated As Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	($2,945)	$5,547
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	16,975	14,343
Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	1,279	3,585
Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	-4,224	1,962
Nondesignated as Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	9,629	-38,737
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	14,680	13,094
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	0	735
Interest Income Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	4,219	3,397
Cost Of Sale [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	2,295	514
Selling, General and Administrative Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	$5,410	($42,134)

Other_Comprehensive_Income_Rol

Other Comprehensive Income - Rollforward (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Balance	'	'	($549,762)	($489,244)
Other comprehensive income (loss) before reclassifications	-11,343	-122,468	'	'
AOCI reclassifications	17,635	17,859	'	'
Other comprehensive income loss net of taxes	6,292	-104,609	'	'
Ending Balance OCI	-543,470	-593,853	'	'
Accumulated Net Gain Loss From Designated Or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Balance	'	'	-121,856	-138,341
Other comprehensive income (loss) before reclassifications	-2,057	4,902	'	'
AOCI reclassifications	12,146	9,974	'	'
Other comprehensive income loss net of taxes	10,089	14,876	'	'
Ending Balance OCI	-111,767	-123,465	'	'
Accumulate benefit plans adjustment [Member]	'	'	'	'
Balance	'	'	-141,987	-179,423
AOCI reclassifications	5,489	7,885	'	'
Other comprehensive income loss net of taxes	5,489	7,885	'	'
Ending Balance OCI	-136,498	-171,538	'	'
Accumulated translation adjustments (Domain) [Member]	'	'	'	'
Balance	'	'	-286,744	-174,349
Other comprehensive income (loss) before reclassifications	-9,535	-125,052	'	'
Other comprehensive income loss net of taxes	-9,535	-125,052	'	'
Ending Balance OCI	-296,279	-299,401	'	'
Total, before non-controlling interests	'	'	'	'
Balance	'	'	-550,587	-492,113
Other comprehensive income (loss) before reclassifications	-11,592	-120,150	'	'
AOCI reclassifications	17,635	17,859	'	'
Other comprehensive income loss net of taxes	6,043	-102,291	'	'
Ending Balance OCI	-544,544	-594,404	'	'
Noncontrolling interests not subject to put provisions [Member]	'	'	'	'
Balance	'	'	825	2,869
Other comprehensive income (loss) before reclassifications	249	-2,318	'	'
Other comprehensive income loss net of taxes	249	-2,318	'	'
Ending Balance OCI	$1,074	$551	'	'

Other_Comprehensive_Income_Rec

Other Comprehensive Income - Reclassifications (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Other comprehensive income derivatives qualifying as hedges net of tax period increase decrease abstract	'	'	'	'
Interest rate contracts	'	'	$14,680	$13,094
Foreign exchange contracts cost of revenue	'	'	2,295	514
Amount of additional interest expense expected to be reclassified into earnings	'	'	867	735
Total before tax	'	'	16,975	14,343
Tax expense or benefit	'	'	-4,829	-4,369
Net of tax	'	'	12,146	9,974
Other comprehensive income defined benefit plans adjustment net of tax period increase decrease abstract	'	'	'	'
Adjustments related to pension obligations - pretax	4,355	6,390	8,709	12,788
Total before tax benefit plans	'	'	8,709	12,788
Benefit plans tax expense	'	'	-3,220	-4,903
OCI reclassification pensions	'	'	5,489	7,885
Total reclassifications for the period	'	'	$17,635	$17,859

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended			6 Months Ended		3 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
						Segment Total [Member]	Segment Total [Member]	Segment Total [Member]	Segment Total [Member]	North America [Member]	North America [Member]	North America [Member]	North America [Member]	International [Member]	International [Member]	International [Member]	International [Member]	International [Member]	Corporate1 [Member]	Corporate1 [Member]	Corporate1 [Member]	Corporate1 [Member]	Corporate1 [Member]
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net revenue from external customers	$3,834,802	$3,612,515	$7,398,394	$7,076,436	'	$3,817,608	$3,603,569	$7,371,411	$7,059,471	$2,520,988	$2,375,247	$4,913,894	$4,662,497	$1,296,620	$1,228,322	'	$2,457,517	$2,396,974	$17,194	$8,946	'	$26,983	$16,965
revenue from company segment	'	'	'	'	'	2,269	1,771	3,549	2,846	2,269	1,771	3,549	2,846	'	'	'	'	'	-2,269	-1,771	'	-3,549	-2,846
Segment revenue	'	'	'	'	'	3,819,877	3,605,340	7,374,960	7,062,317	2,523,257	2,377,018	4,917,443	4,665,343	1,296,620	1,228,322	'	2,457,517	2,396,974	14,925	7,175	'	23,434	14,119
Segment depreciation and amortization	-168,959	-158,801	-336,126	-315,154	'	-133,485	-127,898	-266,155	-254,205	-87,173	-81,466	-174,822	-161,873	-46,312	-46,432	'	-91,333	-92,332	-35,474	-30,903	'	-69,971	-60,949
Operating income	556,273	544,239	1,001,168	1,037,552	'	643,723	609,134	1,159,731	1,166,799	400,714	390,655	736,276	756,703	243,009	218,479	'	423,455	410,096	-87,450	-64,895	'	-158,563	-129,247
Income from equity method investees	5,969	4,416	18,491	9,224	'	5,969	4,416	18,491	9,224	3,818	2,871	14,368	5,989	2,151	1,545	'	4,123	3,235	0	0	'	0	0
Segment assets	24,145,257	'	24,145,257	'	23,119,906	21,821,868	20,066,557	21,821,868	20,066,557	15,060,591	14,094,573	15,060,591	14,094,573	6,761,277	5,971,984	'	6,761,277	5,971,984	2,323,389	2,261,790	'	2,323,389	2,261,790
thereof investment in equity method investees	737,916	'	737,916	'	664,446	737,916	617,430	737,916	617,430	306,313	247,277	306,313	247,277	431,603	370,153	'	431,603	370,153	0	0	'	0	0
Capital expenditures, acquisitions and investments	517,168	215,880	853,956	435,451	'	464,084	174,123	733,620	369,157	283,350	107,948	488,249	220,280	180,734	66,175	'	245,371	148,877	53,084	41,757	'	120,336	66,294
Exclusion of non-cash acquisitions	'	'	'	'	'	'	'	'	'	$6,000	'	'	'	$1,731	'	$8,884	'	'	'	'	$2,125	'	'

Supplementary_Cash_Flow_Inform2

Supplementary Cash Flow Information (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Supplementary cash flow information:	'	'
Cash paid for interest	$189,038	$191,259
Cash paid for income taxes, net of tax refund	304,785	225,740
deferred tax expense from stock options	3,153	3,933
Supplemental disclosures of cash flow information, details for acquisitions:	'	'
Assets acquired	523,912	130,864
Liabilities assumed	241,132	17,173
Noncontrolling interest	6,191	5,570
Notes assumed in connection with acquisition	9,156	11,683
Noncontrolling Interest Subject To Put Provisions	3,110	15,320
Cash Paid	-264,323	-81,118
Less cash acquired in acquisition	84,694	5,139
Net cash paid for acquisitions	-179,629	-75,979
Cash paid for investments	-249,156	-22,894
Cash paid for intangible assets	-5,912	-2,936
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	($434,697)	($101,809)

Supplemental_Condensed_Combini2

Supplemental Condensed Combining Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Income	'	'	'	'	'	'	'
Net revenue	$3,834,802	$3,612,515	$7,398,394	$7,076,436	'	'	'
Cost of revenues	2,623,384	2,454,142	5,104,844	4,808,545	'	'	'
Gross profit	1,211,418	1,158,373	2,293,550	2,267,891	'	'	'
Research and development	30,701	30,921	60,729	61,293	'	'	'
Operating income	556,273	544,239	1,001,168	1,037,552	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Gain on the sale of dialysis clinics	228	7,727	230	8,800	'	'	'
Income before income taxes	457,867	441,188	806,501	830,272	'	'	'
Income tax expense	177,291	143,613	278,575	272,614	'	'	'
Net Income	280,576	297,575	527,926	557,658	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	7,071	3,993	14,030	19,890	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,355	6,390	8,709	12,788	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	37,770	-59,178	-9,286	-127,370	'	'	'
Other comprehensive income loss tax	-3,611	-3,233	-7,161	-9,917	'	'	'
Less: Net income attributable to noncontrolling interests	46,934	35,051	88,822	69,635	'	'	'
Income attributable to the Company	233,642	262,524	439,104	488,023	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	644,538	'	644,538	'	682,777	682,777	688,040
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	3,176,410	'	3,176,410	'	'	3,037,274	'
Accounts receivable from related parties	201,784	'	201,784	'	'	153,118	'
Inventories	1,279,427	'	1,279,427	'	'	1,097,104	'
Prepaid expenses and other current assets	1,248,233	'	1,248,233	'	'	1,037,391	'
Deferred tax asset, current	254,768	'	254,768	'	'	279,052	'
Total current assets	6,805,160	'	6,805,160	'	'	6,286,716	'
Property, plant and equipment, net	3,299,880	'	3,299,880	'	'	3,091,954	'
Intangible assets	728,093	'	728,093	'	'	757,876	'
Goodwill	11,873,989	'	11,873,989	'	'	11,658,187	'
Deferred tax asset, non-current	117,461	'	117,461	'	'	104,167	'
Total assets	24,145,257	'	24,145,257	'	'	23,119,906	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable	559,031	'	559,031	'	'	542,597	'
Accounts payable to related parties	164,499	'	164,499	'	'	123,929	'
Accrued expenses and other current liabilities	2,054,683	'	2,054,683	'	'	2,012,533	'
Short-term borrowings and other financial liabilities	197,804	'	197,804	'	'	96,648	'
Short Term Borrowings Due To Related Parties Current Acquisitions	161,984	'	161,984	'	'	62,342	'
Current portion of long-term debt and capital lease obligations	335,416	'	335,416	'	'	511,370	'
Income tax payable, current	178,032	'	178,032	'	'	170,360	'
Deferred tax liability, current	35,472	'	35,472	'	'	34,194	'
Total current liabilities	3,686,921	'	3,686,921	'	'	3,553,973	'
Total long-term debt less current maturities	8,444,284	'	8,444,284	'	'	7,746,920	'
Other liabilities	337,147	'	337,147	'	'	329,561	'
Pension liabilities	436,711	'	436,711	'	'	435,858	'
Income tax payable, non-current	185,476	'	185,476	'	'	176,933	'
Deferred tax liability, non-current	732,330	'	732,330	'	'	743,390	'
Total liabilities	13,822,869	'	13,822,869	'	'	12,986,635	'
Noncontrolling interests subject to put provisions	672,234	'	672,234	'	'	648,251	'
Company shareholders' equity	9,381,668	'	9,381,668	'	'	9,234,564	'
Minority interest	268,486	'	268,486	'	'	250,456	'
Total equity	9,650,154	'	9,650,154	'	'	9,485,020	'
Total liabilities and equity	24,145,257	'	24,145,257	'	'	23,119,906	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	280,576	297,575	527,926	557,658	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	7,071	3,993	14,030	19,890	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,355	6,390	8,709	12,788	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	37,770	-59,178	-9,286	-127,370	'	'	'
Other comprehensive income loss tax	-3,611	-3,233	-7,161	-9,917	'	'	'
Other comprehensive income (loss), net of tax	45,585	-52,028	6,292	-104,609	'	'	'
Total comprehensive income	326,161	245,547	534,218	453,049	'	'	'
Comprehensive income attributable to noncontrolling interests	-47,216	-34,715	-89,071	-67,317	'	'	'
Comprehensive income attributable to the Company	278,945	210,832	445,147	385,732	'	'	'
Issuers [Member] | FMC US Finance [Member]	'	'	'	'	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Interest, net	'	'	'	-3,417	'	'	'
Income before income taxes	'	'	3,461	3,417	'	'	'
Income tax expense	'	'	1,273	1,240	'	'	'
Net Income	'	'	2,188	2,177	'	'	'
Income attributable to the Company	'	'	2,188	2,177	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	0	1	0	1	'	'	1
Accounts receivable from related parties	1,267,108	'	1,267,108	'	'	1,269,092	'
Total current assets	1,267,108	'	1,267,108	'	'	1,269,092	'
Total assets	1,267,108	'	1,267,108	'	'	1,269,092	'
Current liabilities:	'	'	'	'	'	'	'
Accrued expenses and other current liabilities	29,771	'	29,771	'	'	29,770	'
Total current liabilities	29,771	'	29,771	'	'	29,770	'
Total long-term debt less current maturities	1,165,000	'	1,165,000	'	'	1,167,466	'
Income tax payable, non-current	580	'	580	'	'	2,287	'
Total liabilities	1,195,351	'	1,195,351	'	'	1,199,523	'
Company shareholders' equity	71,757	'	71,757	'	'	69,569	'
Total equity	71,757	'	71,757	'	'	69,569	'
Total liabilities and equity	1,267,108	'	1,267,108	'	'	1,269,092	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	2,188	2,177	'	'	'
Total comprehensive income	'	'	2,188	2,177	'	'	'
Comprehensive income attributable to the Company	'	'	2,188	2,177	'	'	'
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'	'
Selling, general and administrative	'	'	83,548	40,547	'	'	'
Operating income	'	'	-83,548	-40,547	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Interest, net	'	'	122,940	95,049	'	'	'
Other, net	'	'	-671,761	-615,001	'	'	'
Income before income taxes	'	'	465,273	479,405	'	'	'
Income tax expense	'	'	26,169	-8,618	'	'	'
Net Income	'	'	439,104	488,023	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	16,076	14,431	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	99	65	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	36,765	27,707	'	'	'
Other comprehensive income loss tax	'	'	-4,646	-4,162	'	'	'
Income attributable to the Company	'	'	439,104	488,023	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	2,611	4,932	2,611	4,932	'	13	78
Accounts receivable from related parties	1,351,662	'	1,351,662	'	'	960,137	'
Prepaid expenses and other current assets	49,754	'	49,754	'	'	71,939	'
Total current assets	1,404,027	'	1,404,027	'	'	1,032,089	'
Property, plant and equipment, net	651	'	651	'	'	734	'
Intangible assets	270	'	270	'	'	501	'
Deferred tax asset, non-current	85,060	'	85,060	'	'	80,931	'
Other assets	14,258,249	'	14,258,249	'	'	13,955,933	'
Total assets	15,748,257	'	15,748,257	'	'	15,070,188	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable	651	'	651	'	'	2,193	'
Accounts payable to related parties	2,032,970	'	2,032,970	'	'	1,896,712	'
Accrued expenses and other current liabilities	54,308	'	54,308	'	'	45,897	'
Short-term borrowings and other financial liabilities	68,290	'	68,290	'	'	60	'
Current portion of long-term debt and capital lease obligations	68,749	'	68,749	'	'	271,090	'
Income tax payable, current	117,578	'	117,578	'	'	114,197	'
Deferred tax liability, current	1,259	'	1,259	'	'	2,331	'
Total current liabilities	2,343,805	'	2,343,805	'	'	2,332,480	'
Total long-term debt less current maturities	646,406	'	646,406	'	'	96,699	'
Long term borrowings from related parties	3,328,094	'	3,328,094	'	'	3,359,606	'
Other liabilities	5,340	'	5,340	'	'	5,616	'
Pension liabilities	12,395	'	12,395	'	'	10,377	'
Income tax payable, non-current	30,549	'	30,549	'	'	30,846	'
Total liabilities	6,366,589	'	6,366,589	'	'	5,835,624	'
Company shareholders' equity	9,381,668	'	9,381,668	'	'	9,234,564	'
Total equity	9,381,668	'	9,381,668	'	'	9,234,564	'
Total liabilities and equity	15,748,257	'	15,748,257	'	'	15,070,188	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	439,104	488,023	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	16,076	14,431	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	99	65	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	36,765	27,707	'	'	'
Other comprehensive income loss tax	'	'	-4,646	-4,162	'	'	'
Other comprehensive income (loss), net of tax	'	'	48,294	38,041	'	'	'
Total comprehensive income	'	'	487,398	526,064	'	'	'
Comprehensive income attributable to the Company	'	'	487,398	526,064	'	'	'
Guarantors [Member] | D GmbH [Member]	'	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'	'
Net revenue	'	'	1,092,279	1,006,662	'	'	'
Cost of revenues	'	'	691,930	663,055	'	'	'
Gross profit	'	'	400,349	343,607	'	'	'
Selling, general and administrative	'	'	84,853	106,983	'	'	'
Research and development	'	'	38,761	36,549	'	'	'
Operating income	'	'	276,735	200,075	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Interest, net	'	'	-2,928	3,804	'	'	'
Other, net	'	'	202,485	164,333	'	'	'
Income before income taxes	'	'	77,178	31,938	'	'	'
Income tax expense	'	'	74,033	37,248	'	'	'
Net Income	'	'	3,145	-5,310	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	1,894	1,267	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-7,260	-6,535	'	'	'
Other comprehensive income loss tax	'	'	-553	-369	'	'	'
Income attributable to the Company	'	'	3,145	-5,310	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	8,033	595	8,033	595	'	4,490	501
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	154,243	'	154,243	'	'	152,480	'
Accounts receivable from related parties	1,040,410	'	1,040,410	'	'	815,748	'
Inventories	314,662	'	314,662	'	'	287,625	'
Prepaid expenses and other current assets	56,457	'	56,457	'	'	41,240	'
Total current assets	1,573,805	'	1,573,805	'	'	1,301,583	'
Property, plant and equipment, net	257,430	'	257,430	'	'	238,469	'
Intangible assets	68,318	'	68,318	'	'	73,166	'
Goodwill	62,223	'	62,223	'	'	62,829	'
Deferred tax asset, non-current	14,829	'	14,829	'	'	14,209	'
Other assets	57,611	'	57,611	'	'	47,661	'
Total assets	2,034,216	'	2,034,216	'	'	1,737,917	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable	32,873	'	32,873	'	'	28,689	'
Accounts payable to related parties	785,342	'	785,342	'	'	522,719	'
Accrued expenses and other current liabilities	154,350	'	154,350	'	'	129,727	'
Deferred tax liability, current	10,598	'	10,598	'	'	9,002	'
Total current liabilities	983,163	'	983,163	'	'	690,137	'
Other liabilities	5,644	'	5,644	'	'	6,028	'
Pension liabilities	261,351	'	261,351	'	'	254,233	'
Total liabilities	1,250,158	'	1,250,158	'	'	950,398	'
Company shareholders' equity	784,058	'	784,058	'	'	787,519	'
Total equity	784,058	'	784,058	'	'	787,519	'
Total liabilities and equity	2,034,216	'	2,034,216	'	'	1,737,917	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	3,145	-5,310	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	1,894	1,267	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-7,260	-6,535	'	'	'
Other comprehensive income loss tax	'	'	-553	-369	'	'	'
Other comprehensive income (loss), net of tax	'	'	-5,919	-5,637	'	'	'
Total comprehensive income	'	'	-2,774	-10,947	'	'	'
Comprehensive income attributable to the Company	'	'	-2,774	-10,947	'	'	'
Guarantors [Member] | FMCH [Member]	'	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'	'
Selling, general and administrative	'	'	-24,234	37,920	'	'	'
Operating income	'	'	24,234	-37,920	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Interest, net	'	'	90,665	87,078	'	'	'
Other, net	'	'	-374,253	-432,819	'	'	'
Income before income taxes	'	'	307,822	307,821	'	'	'
Income tax expense	'	'	-26,207	-49,312	'	'	'
Net Income	'	'	334,029	357,133	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	6,524	11,335	'	'	'
Other comprehensive income loss tax	'	'	-2,574	-4,472	'	'	'
Income attributable to the Company	'	'	334,029	357,133	'	'	'
Current assets:	'	'	'	'	'	'	'
Accounts receivable from related parties	1,654,545	'	1,654,545	'	'	1,643,394	'
Prepaid expenses and other current assets	67	'	67	'	'	167	'
Total current assets	1,654,612	'	1,654,612	'	'	1,643,561	'
Other assets	12,894,961	'	12,894,961	'	'	12,583,487	'
Total assets	14,549,573	'	14,549,573	'	'	14,227,048	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable to related parties	1,602,668	'	1,602,668	'	'	1,600,480	'
Accrued expenses and other current liabilities	9,346	'	9,346	'	'	9,403	'
Current portion of long-term debt and capital lease obligations	200,000	'	200,000	'	'	200,000	'
Total current liabilities	1,812,014	'	1,812,014	'	'	1,809,883	'
Total long-term debt less current maturities	2,435,447	'	2,435,447	'	'	2,438,189	'
Long term borrowings from related parties	2,076,579	'	2,076,579	'	'	2,092,818	'
Other liabilities	0	'	0	'	'	0	'
Total liabilities	6,324,040	'	6,324,040	'	'	6,340,890	'
redeemable preferred stock	235,141	'	235,141	'	'	235,141	'
Company shareholders' equity	7,990,392	'	7,990,392	'	'	7,651,017	'
Total equity	7,990,392	'	7,990,392	'	'	7,651,017	'
Total liabilities and equity	14,549,573	'	14,549,573	'	'	14,227,048	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	334,029	357,133	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	6,524	11,335	'	'	'
Other comprehensive income loss tax	'	'	-2,574	-4,472	'	'	'
Other comprehensive income (loss), net of tax	'	'	3,950	6,863	'	'	'
Total comprehensive income	'	'	337,979	363,996	'	'	'
Comprehensive income attributable to the Company	'	'	337,979	363,996	'	'	'
Non Guarantor Subsidiaries [Member]	'	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'	'
Net revenue	'	'	8,085,343	7,664,410	'	'	'
Cost of revenues	'	'	6,160,749	5,719,837	'	'	'
Gross profit	'	'	1,924,594	1,944,573	'	'	'
Selling, general and administrative	'	'	1,074,154	964,028	'	'	'
Research and development	'	'	21,968	24,912	'	'	'
Operating income	'	'	828,472	955,633	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Interest, net	'	'	-12,549	24,349	'	'	'
Income before income taxes	'	'	841,021	931,284	'	'	'
Income tax expense	'	'	345,468	322,357	'	'	'
Net Income	'	'	495,553	559,265	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	-2,046	5,459	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	192	121	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-38,509	-154,575	'	'	'
Other comprehensive income loss tax	'	'	612	-914	'	'	'
Income attributable to the Company	'	'	495,553	608,927	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	632,579	550,768	632,579	550,768	'	672,206	686,457
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	3,020,417	'	3,020,417	'	'	2,882,736	'
Accounts receivable from related parties	4,297,558	'	4,297,558	'	'	4,073,975	'
Inventories	1,129,355	'	1,129,355	'	'	946,790	'
Prepaid expenses and other current assets	1,090,101	'	1,090,101	'	'	879,085	'
Deferred tax asset, current	299,458	'	299,458	'	'	322,337	'
Total current assets	10,469,468	'	10,469,468	'	'	9,777,129	'
Property, plant and equipment, net	3,168,807	'	3,168,807	'	'	2,980,268	'
Intangible assets	659,594	'	659,594	'	'	684,290	'
Goodwill	11,811,766	'	11,811,766	'	'	11,595,358	'
Deferred tax asset, non-current	128,624	'	128,624	'	'	118,306	'
Other assets	5,068,002	'	5,068,002	'	'	5,234,132	'
Total assets	31,306,261	'	31,306,261	'	'	30,389,483	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable	525,507	'	525,507	'	'	511,715	'
Accounts payable to related parties	5,394,855	'	5,394,855	'	'	4,931,344	'
Accrued expenses and other current liabilities	1,802,668	'	1,802,668	'	'	1,786,709	'
Short-term borrowings and other financial liabilities	129,514	'	129,514	'	'	96,588	'
Short Term Borrowings Due To Related Parties Current Acquisitions	161,984	'	161,984	'	'	62,342	'
Current portion of long-term debt and capital lease obligations	66,667	'	66,667	'	'	40,280	'
Income tax payable, current	58,684	'	58,684	'	'	56,163	'
Deferred tax liability, current	66,651	'	66,651	'	'	64,539	'
Total current liabilities	8,206,530	'	8,206,530	'	'	7,549,680	'
Total long-term debt less current maturities	7,390,784	'	7,390,784	'	'	7,478,944	'
Long term borrowings from related parties	5,985	'	5,985	'	'	6,940	'
Other liabilities	302,918	'	302,918	'	'	298,313	'
Pension liabilities	162,965	'	162,965	'	'	171,248	'
Income tax payable, non-current	24,791	'	24,791	'	'	20,262	'
Deferred tax liability, non-current	757,995	'	757,995	'	'	768,156	'
Total liabilities	16,851,968	'	16,851,968	'	'	16,293,543	'
Noncontrolling interests subject to put provisions	672,234	'	672,234	'	'	648,251	'
redeemable preferred stock	-235,141	'	-235,141	'	'	-235,141	'
Company shareholders' equity	13,748,714	'	13,748,714	'	'	13,432,374	'
Minority interest	268,486	'	268,486	'	'	250,456	'
Total equity	14,017,200	'	14,017,200	'	'	13,682,830	'
Total liabilities and equity	31,306,261	'	31,306,261	'	'	30,389,483	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	495,553	559,265	'	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	'	'	-2,046	5,459	'	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	'	'	192	121	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-38,509	-154,575	'	'	'
Other comprehensive income loss tax	'	'	612	-914	'	'	'
Other comprehensive income (loss), net of tax	'	'	-39,751	-149,909	'	'	'
Total comprehensive income	'	'	455,802	459,018	'	'	'
Comprehensive income attributable to the Company	'	'	455,802	459,018	'	'	'
Combining Adjustment [Member]	'	'	'	'	'	'	'
Consolidated Statements of Income	'	'	'	'	'	'	'
Net revenue	'	'	-1,779,228	-1,594,636	'	'	'
Cost of revenues	'	'	-1,747,835	-1,574,347	'	'	'
Gross profit	'	'	-31,393	-20,289	'	'	'
Selling, general and administrative	'	'	13,332	19,568	'	'	'
Research and development	'	'	0	-168	'	'	'
Operating income	'	'	-44,725	-39,689	'	'	'
Other (income) expense:	'	'	'	'	'	'	'
Other, net	'	'	843,529	883,487	'	'	'
Income before income taxes	'	'	-888,254	-923,593	'	'	'
Income tax expense	'	'	-142,161	-30,301	'	'	'
Net Income	'	'	-746,093	-843,630	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-282	6,033	'	'	'
Less: Net income attributable to noncontrolling interests	'	'	88,822	69,635	'	'	'
Income attributable to the Company	'	'	-834,915	-962,927	'	'	'
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	1,315	29,561	1,315	29,561	'	6,068	1,003
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	1,750	'	1,750	'	'	2,058	'
Accounts receivable from related parties	-9,409,499	'	-9,409,499	'	'	-8,609,228	'
Inventories	-164,590	'	-164,590	'	'	-137,311	'
Prepaid expenses and other current assets	51,854	'	51,854	'	'	44,960	'
Deferred tax asset, current	-44,690	'	-44,690	'	'	-43,285	'
Total current assets	-9,563,860	'	-9,563,860	'	'	-8,736,738	'
Property, plant and equipment, net	-127,008	'	-127,008	'	'	-127,517	'
Intangible assets	-89	'	-89	'	'	-81	'
Deferred tax asset, non-current	-111,052	'	-111,052	'	'	-109,279	'
Other assets	-30,958,149	'	-30,958,149	'	'	-30,600,207	'
Total assets	-40,760,158	'	-40,760,158	'	'	-39,573,822	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable to related parties	-9,651,336	'	-9,651,336	'	'	-8,827,326	'
Accrued expenses and other current liabilities	4,240	'	4,240	'	'	11,027	'
Income tax payable, current	1,770	'	1,770	'	'	'	'
Deferred tax liability, current	-43,036	'	-43,036	'	'	-41,678	'
Total current liabilities	-9,688,362	'	-9,688,362	'	'	-8,857,977	'
Total long-term debt less current maturities	-3,193,353	'	-3,193,353	'	'	-3,434,378	'
Long term borrowings from related parties	-5,410,658	'	-5,410,658	'	'	-5,459,364	'
Other liabilities	23,245	'	23,245	'	'	19,604	'
Pension liabilities	0	'	0	'	'	'	'
Income tax payable, non-current	129,556	'	129,556	'	'	123,538	'
Deferred tax liability, non-current	-25,665	'	-25,665	'	'	-24,766	'
Total liabilities	-18,165,237	'	-18,165,237	'	'	-17,633,343	'
Company shareholders' equity	-22,594,921	'	-22,594,921	'	'	-21,940,479	'
Total equity	-22,594,921	'	-22,594,921	'	'	-21,940,479	'
Total liabilities and equity	-40,760,158	'	-40,760,158	'	'	-39,573,822	'
Consolidated Statements of Comprehensive Income	'	'	'	'	'	'	'
Net Income	'	'	-746,093	-843,630	'	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	'	'	-282	6,033	'	'	'
Other comprehensive income (loss), net of tax	'	'	-282	6,033	'	'	'
Total comprehensive income	'	'	-746,375	-887,259	'	'	'
Comprehensive income attributable to noncontrolling interests	'	'	-89,071	-67,317	'	'	'
Comprehensive income attributable to the Company	'	'	($835,446)	($954,576)	'	'	'

Supplemental_Condensed_Combini3

Supplemental Condensed Combining Information (Details 1) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating Activities:	'	'	'	'
Net Income	$280,576	$297,575	$527,926	$557,658
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	336,126	315,154
Change in deferred taxes, net	'	'	692	-529
Stock Option Compensation Expense	'	'	-1,403	12,777
Dividend income from equity method investees	'	'	28,737	14,751
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	-93,529	-62,574
Inventories, net	'	'	-180,098	-34,265
Prepaid expenses, other current and non-current assets	'	'	-66,742	22,735
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	-7,651	-9,009
Income tax payable	'	'	1,818	12,801
Net cash provided by (used in) operating activities	'	'	561,607	840,537
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-419,259	-333,642
Proceeds from sale of property, plant and equipment	'	'	4,291	14,796
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-434,697	-101,809
Proceeds from divestitures	'	'	3,310	17,824
Net cash (used in) provided by investing activities	'	'	-846,355	-402,831
Financing Activities:	'	'	'	'
Increase (decrease) of accounts receivable securitization program	'	'	72,000	23,000
Proceeds from exercise of stock options	'	'	40,753	36,142
Distributions to noncontrolling interests	'	'	'	117,855
Contributions from noncontrolling interests	'	'	25,323	27,157
Net cash (used in) provided by financing activities	'	'	247,370	-524,121
Effect of exchange rate changes on cash and cash equivalents	'	'	-861	-15,768
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-38,239	-102,183
Cash and cash equivalents at beginning of period	682,777	'	682,777	688,040
Cash and cash equivalents at end of period	644,538	'	644,538	'
Issuers [Member] | FMC US Finance [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	2,188	2,177
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Accounts receivable from/payable to related parties	'	'	-406	410
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	0	0
Income tax payable	'	'	-1,707	520
Net cash provided by (used in) operating activities	'	'	75	2,287
Financing Activities:	'	'	'	'
Long-term debt and capital lease obligations, net	'	'	-75	-2,287
Net cash (used in) provided by financing activities	'	'	-75	-2,287
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	0	0
Cash and cash equivalents at beginning of period	'	'	'	1
Cash and cash equivalents at end of period	0	1	0	1
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	439,104	488,023
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	-315,283	-331,592
Depreciation and amortization	'	'	340	330
Change in deferred taxes, net	'	'	-10,662	-19,248
(Gain) loss on sale of fixed assets and investments	'	'	'	-12
Write-off of loans from related parties	'	'	54,541	'
Stock Option Compensation Expense	'	'	-1,403	12,777
Cash outflow from hedging	'	'	'	4,028
Dividend income from equity method investees	'	'	-43,411	-22,691
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Prepaid expenses, other current and non-current assets	'	'	34,643	10,768
Accounts receivable from/payable to related parties	'	'	-169,605	-286,966
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	17,335	10,171
Income tax payable	'	'	4,497	729
Net cash provided by (used in) operating activities	'	'	96,918	477,575
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	37	45
Proceeds from sale of property, plant and equipment	'	'	'	17
Disbursements of loans to related parties	'	'	-194,357	-45,738
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	197,807	23,076
Net cash (used in) provided by investing activities	'	'	-392,201	22,634
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	226,862	4
Long-term debt and capital lease obligations, net	'	'	351,059	'
Proceeds from exercise of stock options	'	'	-37,604	-32,210
Payment of dividends [N]	'	'	317,903	'
Net cash (used in) provided by financing activities	'	'	297,622	-494,220
Effect of exchange rate changes on cash and cash equivalents	'	'	259	-1,135
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	2,598	4,854
Cash and cash equivalents at beginning of period	'	'	13	78
Cash and cash equivalents at end of period	2,611	4,932	2,611	4,932
Guarantors [Member] | D GmbH [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	3,145	-5,310
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	26,497	24,691
Change in deferred taxes, net	'	'	411	3,651
(Gain) loss on sale of fixed assets and investments	'	'	-107	-153
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	-3,245	-11,574
Inventories, net	'	'	-29,910	-24,736
Prepaid expenses, other current and non-current assets	'	'	-14,866	-17,389
Accounts receivable from/payable to related parties	'	'	218,846	-68,660
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	41,603	38,199
Net cash provided by (used in) operating activities	'	'	242,374	76,039
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	43,687	39,394
Proceeds from sale of property, plant and equipment	'	'	-188	'
Disbursements of loans to related parties	'	'	'	271
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	11,372	1,943
Net cash (used in) provided by investing activities	'	'	-54,871	-41,066
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	-183,906	-34,873
Net cash (used in) provided by financing activities	'	'	-183,906	-34,873
Effect of exchange rate changes on cash and cash equivalents	'	'	-54	-6
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	3,543	94
Cash and cash equivalents at beginning of period	'	'	4,490	501
Cash and cash equivalents at end of period	8,033	595	8,033	595
Guarantors [Member] | FMCH [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	334,029	357,133
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	-374,253	-432,819
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Prepaid expenses, other current and non-current assets	'	'	-21,933	40,202
Accounts receivable from/payable to related parties	'	'	28,110	-57,847
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	-57	106
Income tax payable	'	'	-26,207	-49,312
Net cash provided by (used in) operating activities	'	'	-60,311	-26,843
Investing Activities:	'	'	'	'
Disbursements of loans to related parties	'	'	101,745	-28,419
Net cash (used in) provided by investing activities	'	'	101,745	28,419
Financing Activities:	'	'	'	'
Long-term debt and capital lease obligations, net	'	'	-41,434	1,697,512
Capital (decrease) increase	'	'	'	0
Net cash (used in) provided by financing activities	'	'	-41,434	-1,576
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	0	'
Non Guarantor Subsidiaries [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	495,553	559,265
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	'	'	327,154	305,236
Change in deferred taxes, net	'	'	19,178	24,404
(Gain) loss on sale of fixed assets and investments	'	'	1,651	-6,089
Dividend income from equity method investees	'	'	14,674	7,940
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	-90,574	-51,000
Inventories, net	'	'	-181,345	-29,542
Prepaid expenses, other current and non-current assets	'	'	-59,782	-39,431
Accounts receivable from/payable to related parties	'	'	-75,880	462,322
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	-65,393	-53,631
Income tax payable	'	'	16,137	35,551
Net cash provided by (used in) operating activities	'	'	372,025	324,163
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	394,161	311,089
Proceeds from sale of property, plant and equipment	'	'	-4,103	14,508
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	434,570	100,883
Proceeds from divestitures	'	'	-3,310	17,824
Net cash (used in) provided by investing activities	'	'	-821,318	-379,640
Financing Activities:	'	'	'	'
Short-term borrowings, net	'	'	145,323	35,808
Long-term debt and capital lease obligations, net	'	'	119,027	-1,736,452
Increase (decrease) of accounts receivable securitization program	'	'	72,000	-23,000
Proceeds from exercise of stock options	'	'	-3,149	-3,932
Capital (decrease) increase	'	'	-142,957	0
Distributions to noncontrolling interests	'	'	97,047	-682,564
Contributions from noncontrolling interests	'	'	25,323	'
Net cash (used in) provided by financing activities	'	'	410,732	-65,585
Effect of exchange rate changes on cash and cash equivalents	'	'	-1,066	-14,627
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-39,627	-135,689
Cash and cash equivalents at beginning of period	'	'	672,206	686,457
Cash and cash equivalents at end of period	632,579	550,768	632,579	550,768
Combining Adjustment [Member]	'	'	'	'
Operating Activities:	'	'	'	'
Net Income	'	'	-746,093	-843,630
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	'	'	689,536	714,749
Depreciation and amortization	'	'	-17,865	-15,103
Change in deferred taxes, net	'	'	-8,235	-9,336
Write-off of loans from related parties	'	'	-54,541	'
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'	'	'
Trade accounts receivable, net	'	'	290	'
Inventories, net	'	'	31,157	20,013
Prepaid expenses, other current and non-current assets	'	'	-4,804	28,585
Accounts receivable from/payable to related parties	'	'	13,122	-70,579
Accounts payable, accrued expenses and other current and non-current liabilities	'	'	-1,139	-3,854
Income tax payable	'	'	9,098	25,313
Net cash provided by (used in) operating activities	'	'	-89,474	-12,684
Investing Activities:	'	'	'	'
Purchases of property, plant and equipment	'	'	-18,626	-16,886
Disbursements of loans to related parties	'	'	92,612	74,157
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	'	'	-209,052	-24,093
Proceeds from divestitures	'	'	'	0
Net cash (used in) provided by investing activities	'	'	320,290	-33,178
Financing Activities:	'	'	'	'
Long-term debt and capital lease obligations, net	'	'	-92,612	74,157
Capital (decrease) increase	'	'	142,957	0
Net cash (used in) provided by financing activities	'	'	-235,569	74,420
Cash and Cash Equivalents:	'	'	'	'
(decrease) in cash and cash equivalents	'	'	-4,753	28,558
Cash and cash equivalents at beginning of period	'	'	6,068	1,003
Cash and cash equivalents at end of period	$1,315	$29,561	$1,315	$29,561